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The occurrence of treatment refractory tumors contributes significantly to the 
morbidity of cancer.  Clinical treatment with chemotherapeutics frequently results in 
robust initial responses but the majority of patients relapse with drug-insensitive forms of 
the disease.  Considering the lack of therapies available to these patients, our labs 
implemented a chemical biology approach towards understanding and defining molecular 
processes of drug-insensitive cancer cells.  A small molecule screen was developed with 
the goal of identifying new molecular tools to characterize vulnerabilities of drug 
refractory tumor cells.  The screen employed malignant pleural effusion cells derived 
from treatment refractory breast cancer patients in addition to untransformed mammary 
epithelial cells; the incorporation of untransformed cells in the screen permitted for the 
identification of small molecules with cancer-specific phenotypes.  Fourteen novel small 
molecules were identified and two of these molecules, C-6 and zinaamidole (ZNA), were 
chosen for detailed follow-up studies.  The first molecule, C-6, was found to be cytotoxic 
against multiple patient-derived malignant cell types in addition to a variety of breast 
cancer cell lines, but did not significantly affect to viability of untransformed cells.  Next-
generation RNA sequencing revealed that C-6 induced endoplasmic reticulum stress and 
blocked mitochondrial genome transcription.  Cells treated with C-6 with disruptions in 
mitochondrial energy production as assessed by oxygen consumption measurements.
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Cancer-specific increases in the oxidation of 2',7'-dichlorodihydrofluorescein diacetate 
were also observed, indicating that cellular redox states were altered by treatment with C-
6.  Finally, C-6 was found to induce cancer cell death via a caspase independent 
mechanism.  The second molecule identified, ZNA, contains a cyclic guanidine core and 
was found to induce metal trafficking gene expression and disrupt Zn2+ homeostasis.  
CuSO4 strongly potentiated ZNA’s cytotoxic effects and treatment with ZNA/CuSO4 
promoted rapid cell death in both malignant and untransformed cell types.  ZnSO4 also 
potentiated ZNA’s cytotoxicity, however, ZNA/ZnSO4 only resulted in cell death in 
malignant cell types.  ZNA and ZNA/ZnSO4 were both found to induce caspase 
independent cell death selectively in cancer cells.  Collectively, these investigations 
revealed a common theme of caspase independent cell death, suggesting a new strategy 
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The prevalence of cancer in society 
Cancer is a leading cause of the death in the United States, second only to heart 
disease in mortality (1).  The impact of the disease is readily apparent when considering 
that one in three women and one in two men will be diagnosed with cancer during their 
lifetime (2).  Cancer, however, is not a recent development in the history of human 
maladies; descriptions of the disease can be found from civilizations existing more than 
3000 years ago (3).  It has long paralleled human existence and has presented a seemingly 
insurmountable challenge to researchers working to eradicate the disease.  Despite 
significant efforts put forth by the clinical and scientific research communities, the 
combined cancer mortality rates of men and women decreased by only 12.1% between 
the years of 1950 and 2010 (2).  This statistic alone illustrates the difficult nature of the 
problem and also alludes to the deep and innate complexity of cancer. 
 
 
Cancer as a heterogeneous disease 
 The biological diversity of cancer contributes to its complexity and results in 
cancer being a collection of diseases rather than a single disorder.  Cancer is the product 
of abnormal cellular growth; growth-deregulated cells propagate and colonize 
environments within healthy tissue and create a burden that terminally impairs the 
function of the healthy tissue, ultimately causing host death.  An individual tumor is 
heterogeneous in nature and comprised of many different tumor cell types that vary in 
cellular function, genetic makeup, and proliferation potential.  Collectively, the different 
populations, or clones, within the tumor coalesce to form complex and dynamic 
ecosystems that vary in their nutrient and oxygen availability, metastatic potential, and 
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proliferation rates.  This dynamic, phenotypic heterogeneity in tumors is widely 
acknowledged and hypothesized to significantly affect clinical treatment outcomes in 
patients.  However, the biological basis for the cellular diversity is not fully understood; 
as such, a better understanding of the source of cellular diversity could play an important 
role in the development of more effective treatment strategies.  Two models have been 
proposed to explain the basis for the cellular heterogeneity observed within tumors and 
more recently, a unified model of the two hypotheses has emerged.  Notably, the 




The cancer stem cell model of tumor heterogeneity 
A single type of tissue within an organism is comprised of different cell types that 
vary in function.  Within the tissue, these cells are organized in a hierarchal manner based 
on their degree of differentiation and functional specialization.  The least specialized, 
least differentiated cells are considered adult stem cells.  Stem cells possess the unique 
ability to self-renew; that is, upon cell division, they can generate either one (asymmetric 
division) or two (symmetric division) exact copies of the mother cell, which then have 
the ability to further produce progeny in a similar fashion (reviewed in (4)).  Adult stem 
cells are responsible for the production of highly specialized, fully differentiated cells 
within tissue.  Analogous to healthy tissue, evidence exists to suggest that tumor tissue, 
being heterogeneous in nature, contains malignant stem cells with self-perpetuating 
potential.  These cells, termed “cancer stem cells” (CSCs), are proposed to engender 
phenotypic and histological heterogeneity within the tumor (5-7). 
4 
	  
Operationally, CSCs are distinguished from other more differentiated cell 
populations within the tumor based on the expression of specific cell surface proteins; 
these proteins also facilitate their fractionation and isolation using fluorescence activated 
cell sorting (FACS).  Multiple cell surface proteins have been identified as markers of 
CSCs and their usage often depends on the origin of the tissue (i.e., lung, liver, brain, 
breast) (reviewed in (8)).  Coupled with the presence of specific cell surface markers, 
Hoechst nuclear staining and subsequent side population analysis by FACS can also 
distinguish CSC populations in some cases (9, 10).  The ability to isolate specific 
populations of cells within a heterogeneous tumor has allowed for variations in 
tumorigenic potential to be studied between cell types.  Studies of this nature have 
revealed that CSCs have a propensity to both initiate tumorigenesis and recapitulate the 
cellular diversity of the parental tumor when transplanted into a whole organism tumor 
model (11-14).  These reports provide experimental evidence in support of the CSC 
model and further suggest that tumor heterogeneity arises from a unique subpopulation of 
cells. 
Collectively, literature reports detailing the frequency of CSCs within bulk tumors 
have indicated that the contribution of CSCs to the overall cell number is highly variable.  
While results from early studies suggested that CSCs were exceedingly rare, more recent 
investigations have revealed that the frequency of CSC occurrence can vary dramatically 
between different malignancies as evidenced by some animal models of cancer and 
different analyses of human cancers (15-18).  However, the use of disparate analytical 
techniques as well as technical variations in cell isolation and transplantation have been 
suggested to contribute at least partially towards the variation observed in CSC frequency 
(19).  Considering the literature as a whole though, CSCs are most often thought to 
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constitute only a small portion of the cell population within solid tumors. 
The CSC model does not address the origin of the CSC and two hypotheses are 
commonly evoked when considering the CSC cell of origin.  In the first hypothesis, CSCs 
are proposed to originate from adult stem or progenitor cells that, upon mutation, become 
tumorigenic; in the second hypothesis, CSCs are proposed to originate from more 
differentiated cells that acquire stem-like properties during the course of transformation.  
These explanations are not considered mutually exclusive and evidence in support of both 
can be found in various reports, suggesting that the development of transformed cells 
with stem-like features is context-dependent (20, 21).  Regardless of a CSC’s cell of 
origin though, the CSC model proposes that only a subset of cells within the tumor are 
ultimately responsible for tumor propagation due to their ability to produce differentiated 
progeny in a hierarchal manner; this differentiated progeny then in turn constitutes the 
cellular heterogeneity observed in tumors. 
 
 
The clonal evolution model of tumor heterogeneity 
Unlike the CSC model of tumor heterogeneity, the clonal evolution model posits 
that cellular diversity in tumors can arise from any somatic cell, regardless of its capacity 
to self-perpetuate and generate more differentiated cell types.  In the clonal evolution 
model, genetic drift and compound mutations produce tumorigenic clones that constantly 
undergo natural selection as the neoplasm grows, producing the variety of cell types 
observed.  The inherent genetic instability of malignant cells further promotes mutations 
and contributes to the likelihood that more diverse, and subsequently more fit, clones will 
be produced (22).  This model was first proposed by Nowell in 1976 and based upon 
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observations that over time, tumors varied in their degree of heterogeneity (23).  Further 
evidence in support of this model can be found in reports detailing the genetic analysis of 
human hepatocellular carcinoma (HCC); Wu and coworkers conducted whole genome 
sequencing experiments using spatially sequential sections of human HCC samples (24).  
Their analyses allowed for the identification of different genetic lineages within the 
tumor and permitted for the development of a model describing the branching evolution.  
In all, the researchers concluded that tumors accrued many mutations throughout the 
course of evolution, but only a small subset of these mutations, termed driver mutations, 
promoted survival advantages, the remainder of the mutations being inert.  In this case, 
the high degree of mutation diversity observed provides support for the clonal expansion 
model of tumor heterogeneity wherein many mutations would be expected in many cell 
types, but only a small number would provide growth and survival advantage. 
 
 
A unified model of tumor heterogeneity 
In all, experimental evidence exists to support both models of genomic and 
phenotypic heterogeneity in tumors, suggesting that the source of cellular diversity may 
be context-dependent and that the models are not mutually exclusive.  In consideration of 
this, a unification of the CSC and clonal evolution models has been proposed (25, 26).  
The unified model states that within a nascent tumor, a cellular hierarchy exists in a 
manner analogous to nonmalignant tissue; at the top of the hierarchy, a CSC or malignant 
cell with stem-like capabilities is responsible for the cellular heterogeneity observed.  As 
tumor growth progresses though, the tumor-initiating cell accumulates mutations that 
promote self-renewal and result in an increased proportion of cells with the capacity to 
7 
	  
generate diverse progeny.  Later stages of tumor growth are therefore marked by 
genetically shallow hierarchies that eventually appear homogeneous.  As such, the 
unified model proposes that CSCs (or tumor-initiating cells) are ultimately responsible 
for tumor heterogeneity but that clonal evolution and selection processes occurs within 
the CSC population over time.  The model also presents an explanation for the variation 
in CSC frequency observed in different tumors since tumors sampled at different stages 
will likely vary in their CSC frequency, genetic composition, and phenotype. 
 
 
Clinical treatment strategies according to tumor heterogeneity models   
Each model of tumor heterogeneity has the potential to greatly impact clinical 
treatment strategies.  Historically, treatment success has been a measure of bulk tumor 
loss; that is, when a therapy stimulates a decrease in the overall size of a tumor or 
decreases overall tumor burden, the therapy is considered successful.  This treatment 
strategy conforms well to the focus of the clonal evolution model wherein every cell has 
the potential to propagate tumor growth.  In opposition to this, the CSC model suggests 
that only CSCs or tumor-initiating cells have the regenerative capacity necessary to 
regrow the tumor; therefore, only therapies targeting tumor-initiating cells will prove 
successful.  The closely related unified model of tumor heterogeneity would also inspire 
treatment options that target CSCs and tumor-initiating cells.  In all though, the three 
models suggest different clinical strategies for the successful treatment of cancer and the 





The advent of chemotherapy as a treatment for cancer 
 Current cancer treatment regimens most often rely upon a combination of 
treatment approaches including surgical resection of the primary tumor, radiation therapy, 
chemotherapy, and immunotherapy.  While the practice of surgical resection has been 
used therapeutically for thousands of years, the concept of chemotherapeutics emerged 
only recently.  After World War I, it was discovered that nitrogen mustards found in the 
chemical warfare agent mustard gas could attenuate lymphoma cell proliferation, albeit 
the effect was temporary (27).  Numerous chemical agents and drugs have since been 
developed for the treatment of cancer and common biological modes of action have 
stratified these agents into distinct drug classes.  Chemotherapeutics can be broadly 
classified as either cytotoxic therapies or targeted therapies; cytotoxic agents target 
rapidly proliferating cells, indiscriminately affecting both transformed and untransformed 
cells, while targeted therapies affect critical biological pathways preferentially in 
transformed cells (reviewed in (28)).  Within these two broad classes of 
chemotherapeutic drugs, additional classifications can be made based on the molecular 
mechanism of action.  Alkylating agents, antimetabolites, and anthracyclines are 
examples of cytotoxic therapies that interfere with DNA synthesis and replication; other 
classes of cytotoxic therapies such as topoisomerase and mitotic inhibitors directly block 
cell cycle progression (reviewed in (29)).  Examples of targeted therapy drug classes 
include hormone receptor modulators, proteasome inhibitors, monoclonal antibodies, and 
small molecule kinase inhibitors. 
The development of cytotoxic and targeted therapies has significantly expanded 
available cancer treatment options; current clinical treatment regimens rely heavily upon 
chemotherapeutics to extend patient survival.  Despite the marked improvement in patient 
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survival achieved through the use of chemotherapeutics though, many patients will still 
ultimately succumb to the disease.  The failure of chemotherapeutics to completely 
eradicate a patient’s disease is due largely to the occurrence of drug resistance.  While 
many tumors initially respond to clinical treatments using chemotherapeutics, drug-
insensitive cancer recurrence is commonly observed; as such, preventing and treating 
chemoresistant tumors could have a significant impact on long-term patient survival. 
 
 
Molecular mechanisms of cancer chemoresistance 
Studies aimed to understand chemoresistance on a cell autonomous level have 
identified two general forms, innate and acquired; additionally, noncell autonomous 
mechanisms have been identified for their role in drug resistance.  The occurrence of 
drug resistance in tumors is strongly correlated with poor patient prognosis; 
understanding the biological basis for the different types of chemoresistance and their 




Innate, cell autonomous drug resistance 
Innate, cell autonomous drug resistance is often attributed to the existence of 
CSCs.  The results of studies designed to elucidate the role of CSCs in drug resistance 
have led to the development of a model wherein CSCs are able to survive drug treatment; 
this small fraction of surviving CSCs are responsible for cancer relapse due to their 
ability to repopulate the bulk tumor (30-32).  To add further complexity to the role of 
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CSCs in tumor progression, Gurney and coworkers concluded from a study in 2008 that 
chemotherapeutic drug treatment could enrich for colorectal CSCs in a mouse xenograft 
model and that regrowth of the population following drug treatment resulted in higher 
levels of CSCs, an observation proposed to be the consequence of a selection process 
(33).  In a subsequent independent investigation, Lokshin and coworkers similarly 
concluded that drug treatment enriched for CSCs by using in vitro models of breast, 
ovarian, and lung cancer (34).  Furthermore, when the drug insensitive CSC-enriched 
fraction was allowed to proliferate, the resulting population was less sensitive to 
subsequent drug treatment, a proposed result of the higher percentage of innate, drug 
resistant CSCs.  Overall, multiple research studies have established a connection between 
CSCs and drug treatment.  This connection has led to the development of a hypothesis 
that suggests that standard clinical chemotherapy treatments may promote CSC 
enrichment and ultimately contribute to drug refractory tumor relapse. 
That cancer stem cells may contribute to drug resistant tumor relapse 
acknowledges a commonly observed characteristic of the cell type: an intrinsic 
insensitivity to cytotoxic insult compared to their more differentiated counterparts.  
Research conducted to establish the biological basis for this phenomenon has led to the 
development of several potential mechanistic explanations including increased expression 
of small molecule efflux transporters, increased expression of intracellular drug 
detoxification enzymes, and highly efficient DNA damage repair mechanisms.   
One parameter frequently used to identify and isolate CSCs by FACS is based on 
the side population (SP) phenotype, the observation that CSCs within a heterogeneous 
cell population resist Hoechst nuclear stain and segregate into a negatively stained side 
population.  Studies by Sorrentino and coworkers undertaken to elucidate the molecular 
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basis for the phenotype revealed ABCG2, an ATP-binding cassette (ABC) transporter 
protein, mediated Hoechst stain efflux, resulting in the negatively stained side population; 
the authors found that ABCG2 was highly expressed in CSCs from a variety of sources 
and proposed its use as a molecular marker for CSC identification (35).  The culmination 
of this and other scientific reports in the field has been the identification of additional 
proteins within the ABC transporter family that are also highly expressed in CSCs 
(reviewed in (36)).  Functionally, these transporters utilize ATP to actively efflux drugs 
from the intracellular space; as such, the high expression of drug efflux proteins in CSCs 
can confer a significant survival advantage to the cell during chemotherapeutic treatment 
compared to the more differentiated population within the bulk tumor.  The increased 
expression of drug efflux proteins therefore constitutes an innate mechanism by which 
some populations of tumor cells can evade clinical therapies. 
The increased expression of intracellular drug detoxification enzymes also 
contributes to CSC survival during drug treatment.  Using an in vitro mammary epithelial 
cell assay, Dontu and coworkers established that the enzyme aldehyde dehydrogenase 1 
(ALDH1) could be used as a marker for the identification of both normal mammary 
epithelial stem cells and breast cancer stem cells (37).  The enzyme ALDH1 oxidizes 
aldehydes to carboxylic acids and its increased expression in stem cells is hypothesized to 
facilitate early normal development by oxidizing retinol to retinoic acid, a tightly 
regulated molecule that signals critical transcriptional activation and repression events 
during embryonic development (38).  In 1984, a correlation between high ALDH1 
expression and cyclophosphamide drug resistance was made using the leukemia cell line 
L1210 (39).  Further investigation revealed that ALDH1 directly acted upon 
cyclophosphamide, oxidizing it to an inactive metabolite, carboxycyclophosphamide, and 
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rendering its drug function inert (40).  Since these initial discoveries connecting ALDH1 
to cyclophosphamide resistance, additional correlations have been made between high 
expression of ALDH enzymes and resistance to other anticancer therapeutics (41, 42).  
As such, heightened expression of detoxification enzymes such as ALDH1 likely 
contributes to innate mechanisms by which CSCs resist drug treatment. 
Altered DNA damage response pathways are also hypothesized to contribute to 
the innate, cell autonomous resistance of CSCs to tumor drug treatment.  All cell types 
within the body must frequently contend with DNA-damaging insults.  DNA lesions can 
occur via many different mechanisms including spontaneous hydrolysis and base 
deamination, exposure to reactive oxygen species generated by metabolic processes, 
exposure to UV light and ionizing radiation, and exposure to external environmental 
mutagens (reviewed in (43, 44)).  In order to cope with the various forms of molecular 
damage induced by these insults, cells utilize multiple repair mechanisms to mitigate 
genomic damage.  Since adult stem cells are responsible for tissue maintenance and 
homeostasis of an organism, genomic integrity must be well preserved to ensure that 
genetic mutations are not transferred to differentiated progeny.  The privileged nature of 
the stem cell therefore necessitates highly efficient mechanisms to both prevent and 
repair damage to the genome.  One general mechanism by which the potential for DNA 
damage can be prevented or lessened in tissue-specific stem cells is through decreased 
rates in cell cycling, or proliferative quiescence; in nontumorigenic settings, the relatively 
dormant nature of adult stem cells offers the advantage of minimizing replication-based 
errors (45-47).  In a tumor setting, however, CSCs possessing this particular feature are 
intrinsically less sensitive to cytotoxic cancer therapeutics that target rapidly proliferating 
cells; drug treatment can therefore enrich for populations with innately slow cell cycles 
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and render the treatment ineffective (48). 
In addition to this general mechanism of CSC drug resistance, more specific 
molecular alterations in DNA damage repair pathways also exist preferentially in CSCs 
over the bulk of tumor cells and contribute to innate, cell autonomous drug resistance. 
Through transcriptional profiling of murine mammary cell populations, Rosen and 
coworkers found that the expression of DNA damage repair genes was increased in the 
CSC population; this transcriptional increase was correlated with more efficient repair of 
ionizing radiation-induced damage compared to the more differentiated cells within the 
tumor (49).  In the context of cancer chemotherapy, increased DNA repair efficiency 
would be expected to impart a certain level of intrinsic resistance to DNA damaging 
therapeutics.  Consistent with this expectation, Rich and coworkers observed that 
compared to neighboring differentiated cells, glioma stem cells were more resistant to 
ionizing radiation due to their increased capacity for DNA repair (31).  Overall, the 
reports of these and others suggest that the efficient mechanisms by which CSCs repair 




Acquired, cell autonomous drug resistance 
Acquired, cell autonomous drug resistance constitutes a significant portion of the 
research conducted on cancer chemoresistance to date.  Drug treatment perturbs the 
dynamic nature of the tumor milieu and accordingly, a tumor can develop adaptive 
responses to manage disruptions.  Multiple adaptive response mechanisms have been 
identified in tumors and generalized mechanisms include drug target modifications, DNA 
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damage repair pathway modifications, and improved drug efflux mechanisms.  These 
adaptive responses can precede drug resistance and contribute to chemotherapeutic 
failures and tumor relapse. 
Drug target modifications leading to decreased drug sensitivity can include both 
direct modification of the drug-protein interface via genetic mutations or increased 
expression of the protein target.  This type of resistance is frequently observed with small 
molecule kinase inhibitors such as imatinib, in the case of chronic myelogenous 
leukemia, and erlotinib, in the case of non-small cell lung cancer (NSCLC) (50-53).  
With both molecules, mutations at the drug-protein interface decrease the binding affinity 
of the drug and result in the emergence of resistance.  In examples such as these, 
synthetic modifications made to the small molecule to reestablish drug sensitivity can 
prolong the therapeutic benefits of targeting the protein. 
Amplified expression of genes encoding for drug-targeted proteins and their 
related pathway proteins also contributes to drug resistance in cancer; however, this form 
of drug resistance is reported to be less prevalent compared to direct mutation of the 
target protein (54).  Utilizing in vitro models of NSCLC, Janne and coworkers reported 
that treatment with an irreversible epidermal growth factor receptor (EGFR) inhibitor 
resulted in the selection of a small subset of cells (6%) harboring an EGFR amplification; 
upon repopulation after treatment, 100% of cells contained the EGFR amplification (55).  
In all, altered drug targets, occurring through either mutations or increased expression, 
can impact the success of targeted cancer therapeutics and result in tumor relapse even 
after a robust initial treatment response. 
Altered DNA damage response (DDR) pathways can also contribute to drug 
resistance.  Most commonly used chemotherapies function mechanistically by interfering 
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with DNA synthesis or replication and include drugs such as cisplatin (a DNA 
crosslinker), cyclophosphamide (a DNA alkylating agent that interferes with replication), 
and doxorubicin (a topoisomerase II inhibitor).  Following a DNA-targeted insult, 
normal, untransformed cells will either arrest the cell cycle and repair the damage or 
initiate cell death, each as a means to maintain long-term genomic integrity; when repair 
processes are utilized, the repair pathway activated depends upon the type of damage 
sustained (for a review of the DNA damage response, see (44)).   In tumor cells, defects 
in specific repair mechanisms can be exploited for treatment gain, as is the case with 
breast cancers harboring BRCA1 and BRCA2 mutations.  With these tumors, the 
homologous recombination (HR) repair pathway is ineffective and cells rely heavily upon 
alternative pathways for DNA damage repair.  Accordingly, in studies conducted by 
Ashworth and coworkers, pharmacologic inhibition of the base excision repair (BER) 
repair pathway in BRCA1- and BRCA2-deficient systems resulted in significant cell death 
in in vitro assays and blocked tumor formation in an in vivo xenograft tumor model (56).  
The profound synthetic lethality observed in this case has generated significant 
enthusiasm in the research community and clinical trials aimed to test this strategy are 
ongoing.  However, indications of resistance have already been reported; secondary 
mutations in Brca1 and Brca2 that restore the function of the HR repair pathway have 
been identified (57, 58).  In addition to this resistance mechanism, Nussenzweig and 
coworkers demonstrated that cells could also utilize other repair pathways, the non-
homologous end joining pathway, as a means to survive drug treatment (59).  Whether 
via pathway reactivation or transfer of the genomic repair burden to alternative repair 
pathways, these examples illustrate how changes in the DDR pathway can facilitate drug 
resistance in tumors treated with DNA damaging chemotherapeutics. 
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The increased capacity of tumor cells to efflux small molecules also represents an 
adaptive response to chemotherapy, wherein increased efflux results in lowered drug 
accumulation, rendering the treatment ineffective.  Similarly to CSCs, ATP-binding 
cassette (ABC) transporter proteins are thought to be responsible for this effect.  By 
profiling 23 drug resistant human cell lines and comparing them to their drug-sensitive 
counterparts, Inazawa and coworkers found that alterations in the copy numbers of ABC 
transporter genes correlated with resistance (60).  More specifically, 19 of the 23 drug-
resistant lines had amplifications in at least one ABC transporter gene, with ABCA3, 
ABCB1, and ABCC9 presenting with greater than a two-fold increase.  While ABCB1 was 
known previously to contribute to acquired resistance, the study also implicated 10 other 
ABC family members whose involvement had not been previously linked.  Together, 
these results suggest that multiple ABC family members may contribute to drug 
resistance by promoting drug efflux. 
Acquired, cell autonomous drug resistance represents a well-studied area of drug 
resistance.  However, the mechanisms of resistance described here represent only a 
fraction of those that have been reported.  Cancer’s genomic instability provides a 
consistent source of cellular variety; coupled with selective pressure from drug treatment, 
the survival of cells with improved fitness characteristics can allow for the tumor to 
circumvent chemotherapeutic treatment.  As such, it is reasonable to consider that 
improved early cancer detection, before the accumulation of mutations and the further 






Non-cell autonomous drug resistance 
Non-cell autonomous drug resistance represents an emerging field of study in 
oncological research; this form of drug resistance describes the contribution of the stroma 
and tumor microenvironment to drug insensitivity in tumors.  It is becoming increasingly 
apparent that non-cell autonomous mechanisms play a significant role in tumor 
progression via the tumor’s ability to manipulate nonmalignant cells and exploit their 
normal function.  Better understanding the interactions of these components of noncell 
autonomous drug resistance with the tumor is therefore vital to developing improved 
strategies to overcome chemoresistance in patients. 
The connective and structurally supportive nonmalignant tissue that surrounds a 
tumor is known as the stroma, which consists of several different cell types; the 
coordinating nature of the stroma and the tumor together form the tumor 
microenvironment.  While the stroma initially exists outside of the nascent tumor, it will 
increasingly incorporate and blend with the tumor as the tumor grows and expands (for a 
review of stromal contribution to neoplastic progression, see (61)).  The stroma can be 
coaxed to facilitate tumor expansion by exposure to growth factors produced by 
malignant cells; several well-studied growth factors known to participate in this process 
include epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-
derived growth factor (PDGF).  Fibroblasts, one of the cell types that comprises the 
nonmalignant stroma, can acquire an “activated” phenotype during tumorigenesis.  The 
resulting cells, referred to as myofibroblasts or carcinoma-associated fibroblasts (CAFs), 
express altered cell surface markers and possess the ability to remodel the structural 
components of the tumor stroma (62-66).  Considering the complex function of the 
stroma in carcinogenesis, it is reasonable to consider that it may also participate in 
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chemoresistance.  Accordingly, Golub and colleagues cultivated 45 cancer cell lines with 
23 different stromal cell lines and found that, in general, the presence of stromal cells 
altered cancer cell sensitivity to chemotherapeutics (67).  Moreover, evidence of 
resistance to targeted therapies, as opposed to conventional cytotoxic therapies, was 
found in 65% of the conditions tested.  While explanations to understand the molecular 
basis for this effect with specific targeted therapies have yet to be determined, evidence 
has been presented to suggest that stromal secretion of hepatocyte growth factor (HGF) 
and subsequent activation of MAPK signaling in BRAF-mutant melanoma cells is 
sufficient to induce resistance to small molecule RAF inhibitors (67).  In all, stromal-
driven resistance to anticancer agents is a largely underdeveloped area of research; the 
sparse number of results that have been reported, however, suggest that the stroma can 
significantly modulate a patient’s response to chemotherapeutic treatment. 
 
 
Strategies for the treatment of chemoresistant tumors 
 The mechanisms by which malignant cells limit the efficacy of cancer treatments 
described herein represent only a fraction of the mechanisms that have been reported; 
however, even from this subset, the diversity of cellular mechanisms is apparent.  As 
such, developing strategies to treat drug-insensitive cancers will require a personalized 
approach and comprehensive knowledge of each patient’s malignancy.  Several 
approaches have been taken to combat frequently occurring forms of resistance, though.  
Two of these strategies include the development of ABC transporter inhibitors and 
pharmacologic agents that target CSCs. 
 A considerable number of studies have been conducted to assess the affects of 
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ABC transporter inhibition on anticancer drug sensitivity with the goal of preventing drug 
efflux.  In early clinical trials, drugs with inhibitor activity that had already obtained 
FDA-approval to treat unrelated medical conditions were used.  However, the first 
clinical trials were unable to demonstrate drug efficacy with these first generation drugs 
and some drugs resulted in significant systemic toxicity (68, 69).  Unfortunately, later 
generation drugs designed to target specific ABC transporters also failed clinical trials, 
with most proving to be ineffective at reversing chemoresistance (70-73).  As a class, 
ABC transporter inhibitors have yet to be implemented in clinical treatment regimens and 
some hypotheses have been proposed to explain their failures in clinical trials including 
off-target actions against unrelated P450 enzymes and poor clinical trial design (i.e., trials 
that examine late stages of chemoresistance) (74, 75). 
 Another strategy currently being explored for the treatment of drug refractory 
cancers is the development of pharmacologic agents that target CSCs.  To date, several 
drugs have been identified for their preferential cytotoxicity towards CSCs.  Low-dose 
metformin, which is used in the treatment of diabetes, was found to selectively eliminate 
CSCs and also promote relapse-free survival in a mouse xenograft tumor model (76).  
Combined with traditional chemotherapeutic drugs to eliminate more differentiated, bulk 
tumor cells, this approach shows promise for the treatment of drug insensitive tumors and 
other reports have identified additional pharmacologic agents that act against CSCs in a 
manner similar to metformin (77, 78).  In addition to strategies designed to directly 
eliminate CSCs, another complementary approach has been proposed: forced 
differentiation.  Lander and colleagues identified the small molecule salinomycin from a 
high throughput screen for its ability to reduce the number of CSCs in a heterogeneous 
cell population compared to treatment with conventional chemotherapeutics (79, 80).  
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Further analysis of salinomycin’s mechanism of action revealed that it reduced CSC 
numbers by inducing differentiation, suggesting that forced CSC differentiation may be a 
viable approach to target innately drug insensitive CSCs in tumors.  In all, the results of 
multiple studies have suggested that targeting CSCs, either by elimination or forced 
differentiation, is a promising approach towards the development of new therapeutics 




The development of chemoresistance in tumors following an initial positive 
response to treatment is commonly observed following the administration of 
chemotherapeutics.  The tumor landscape is heterogeneous and dynamic, with evidence 
to suggest these characteristics become more prominent during tumor progression; as 
such, tumors can utilize an overwhelming number of biological mechanisms to recover 
from the perturbations induced by drug treatment.  The specific resistance mechanisms 
discussed here represent only a small subset of those that have been identified.  The sheer 
number of mechanisms existing has thus presented the greatest challenge for new 
treatment development; currently, only a limited number of clinical treatment strategies 
targeting these mechanisms have been developed.  Furthermore, overcoming the barrier 
of drug insensitivity will likely require detailed knowledge of each tumor’s cellular 
composition and level of heterogeneity before a treatment can be successfully 
implemented.  The work presented herein describes our efforts to identify vulnerabilities 
of chemoresistant cells that can be targeted therapeutically.  With this body of work, we 
aim to both add to our current understanding of cancer biology and provide insight into 
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DEVELOPMENT OF A SCREEN TO IDENTIFY SMALL MOLECULE 


















Results of the studies presented herein have been published: Gligorich KM, Vaden RV, et 
al. (2013) Development of a screen to identify selective small molecules active against 





 The occurrence of treatment refractory tumors contributes significantly to the 
morbidity of cancer.  On a molecular level, a plethora of mechanisms contributing to anti-
cancer drug resistance have been identified.  For this reason, modeling chemoresistance 
and its heterogeneity has presented a challenge to the development of therapeutics that 
are effective against the drug refractory disease.  With the goal of identifying new 
chemical tools for the study of late-stage cancers, we utilized an in vitro model of breast 
cancer that recapitulates clinically relevant features of heterogeneity and drug resistance 
to conduct a small molecule screen.  The model utilizes metastatic cells obtained from the 
pleural effusions of breast cancer patients that have undergone clinical treatment with 
multiple frontline chemotherapeutics; the small molecule screen was designed to identify 
novel compounds that induce cancer cell death.  In all, fourteen small molecules inducing 
cytotoxic, cancer-selective phenotypes were identified.  The incorporation of this 
specialized in vitro model into our chemical biology approach towards understanding 
advanced-stage, drug-insensitive breast cancer has resulted in the identification of new 




 Breast cancer is currently the second leading cause of cancer-related deaths 
among women in the United States and more than 230,000 women were diagnosed with 
the disease in 2013 alone (1).  As with many cancers, one challenge associated with its 
treatment is its heterogeneity.  An individual neoplasm generally contains a variety of cell 
types that can vary significantly in genomic and molecular composition.  Healthy breast 
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tissue is composed of a variety of cell types that coalesce to form the tissue architecture 
and this variety of cell types found in healthy tissue adds an additional layer of 
complexity to tumors arising form the breast.   
Breast cancer cell lines are the most frequently used models of the disease and 
have contributed significantly not only to our understanding of cancer, but also molecular 
biology in general (2, 3).  Different cell lines represent a wide variety of malignancies 
and serve as renewable and standardized resources for disease research.  Furthermore, the 
capacity of cell lines to be expanded has historically allowed for experiments to be 
conducted that require significant amounts of biological material, although newer, more 
sensitive technologies have abrogated this need to some extent. 
 Even though cancer cell lines constitute a vital component of biomedical research 
and they model many aspects of the disease, not all features are accurately represented.  
Specifically, breast cancer cell lines are homogeneous in nature, as a result of selection 
processes during long-term culture, and do not reflect the cellular diversity and 
heterogeneity of the disease found in patients (4, 5).  Additionally, artificial culture 
environments have selected for rapidly proliferating cell populations over time, another 
divergence from the phenotypes observed in patients’ diseases (6, 7).  Finally, breast 
cancer patients are exposed to multiple treatments—radiation, chemotherapy, and 
immunotherapy—which result in tumor adaptation responses and selection processes; 
cancer cell lines are unlikely to accurately model the nuances of these adaptive processes 
in an artificial setting because they lack the necessary interacting systems (e.g., the 
immune system, stroma, etc.).  As such, even though cancer cell lines are valuable 




Late-state, metastatic breast cancer patients often present with malignant pleural 
effusions, a collection of fluid between the parietal and visceral layers of the pleurae.  
The accumulation of fluid in the pleural space prevents the full expansion of the lung and 
results in difficult, shallow breathing.  More than 75% of malignant pleural effusions 
occur in conjunction with lung, breast, or ovarian cancers or lymphoma; the debilitating 
disease complication can result from permeation of the pleural space to interstitial fluid, 
blocked lymphatic drainage, or inflammation (8, 9).  With malignant pleural effusions, 
cancer cells that have metastasized from the primary tumor can reside in this fluid in 
suspension, or near-suspension, and continue to proliferate (10).  As part of a palliative 
care effort, a thoracentesis can be performed to drain the fluid from the pleural space in 
order to ease respiratory discomfort; this process is not curative though, and continued, 
gradual fluid accumulation necessitates multiple medical interventions.  Unfortunately, 
malignant pleural effusions are disease complications associated with late-stage cancers 
and patient survival following diagnosis with the condition is generally less than four 
months (11). 
 The isolation of malignant pleural effusion (PE) cells from patient thoracenteses 
provides a valuable opportunity to study metastatic and late-stage forms of breast cancer 
in a manner that does not require patients to undergo additional medical procedures.  The 
use of PE cells for oncological research has been reported by others but their use is not 
widespread, likely a result of limited patient access at many research institutes and an 
inability to significantly expand these cells in vitro (12-15).  Previously, our group 
reported the results of a study wherein we characterized the molecular and phenotypic 
features of PE cells and measured their sensitivity to different chemotherapeutics (16).  
Briefly, PE cells were obtained from consented breast cancer patients receiving treatment 
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at the Huntsman Cancer Hospital in collaboration with the Biorepository and Molecular 
Pathology group at the Huntsman Cancer Institute.  Following their isolation from the 
drained pleural effusion fluid, these cells were frozen and stored in aliquots for research 
use; as such, the isolated PE cells could be minimally passaged in vitro with the goal of 
reducing their exposure to artificial culture environments that might alter their molecular 
characteristics over time.  Experiments conducted with Dr. Keith Gligorich, a colleague 
at the Huntsman Cancer Institute, revealed that the isolated PE cells were not only 
heterogeneous in nature, but also had dramatically reduced proliferation rates compared 
to commonly used breast cancer cell lines (Figures 2.1 and 2.2).  Additionally, these cells 
varied in their sensitivity to in vitro chemotherapeutic treatments, likely resulting from 
the different treatment histories of the patients from whom they were derived (Figure 
2.3).  In all, patient-derived malignant PE cells were found to recapitulate aspects of the 
disease not represented by breast cancer cell lines and permitted for the development of 
an in vitro model of chemoresistant, late-stage breast cancer.  Herein, the results of a 
small molecule screen utilizing these patient-derived cells are discussed.  These 
experiments have resulted in the identification of novel small molecules with anticancer 
properties that are active against metastatic, patient-derived tumor cells (16).  The small 
molecules identified represent tools that can be used to further probe vulnerabilities of 




In an effort to explore and better understand the characteristics of drug-insensitive 






















Figure 2.1.  Patient-derived malignant pleural effusion (PE) cells are heterogeneous 
in nature.  Short-term culture of PE cells does not alter the cellular composition of the 
total population.  PE1007070, PE1008032, and PE904557a (PE cell samples derived 
from three individual drug refractory breast cancer patients) were stained with markers 




















































Figure 2.2.  Malignant pleural effusion cells derived from breast cancer patients 
have reduced proliferation rates compared to breast cancer cell lines.  Cells were 
cultured with either bromodeoxyuridine (BrdU) or 5-ethynyl-2’-deoxyuridine (EdU) for 
30 minutes or 6 hours; subsequently, genomic incorporation of the nucleoside analog was 
measured by flow cytometry as a measure of cellular proliferation.  The following cell 
types were evaluated: untransformed cell types- MCF-10A (mammary epithelial cell line) 
and hTERT-HMEC (immortalized primary human mammary epithelial cells); malignant 
cell lines- MCF-7, T47D, and MDA-MB-231; patient-derived malignant pleural effusion 
















































































Figure 2.3.  Patient-derived malignant pleural effusion cells obtained from breast 
cancer patients that have developed drug refractory disease display altered 
responses to chemotherapeutics in vitro.  Cells were treated with each 
chemotherapeutic for four days; cell viability was then measured by assessing cellular 
ATP content.  Values plotted represent the mean and standard deviation of three 
replicates.  Breast cancer cell lines evaluated: MCF-7, T47D, MDA-MB-231.  Patient-





































identify small molecule modulators of biological pathways specific to tumor cells and 2) 
use these small molecules to define vulnerabilities existing in drug-insensitive cells.  
First, a screening system was designed to allow for the identification of cancer-selective 
phenotypes; immortalized human mammary epithelial cells (hTERT-HMECs) were 
chosen to represent nontumorigenic cells and PE cells obtained from a single patient were 
chosen to represent tumor cells in the screen.  Upon selecting cell types appropriate for 
the experiment, a library of small molecules was chosen; we sought to employ molecules 
previously untested in biological systems as a means to identify scaffolds with novel 
biological modes of action.  As such, a library of 560 novel compounds containing a 
variety of chemical scaffolds was chosen.  The compounds originated from different labs 
within the University of Utah Department of Chemistry and a variety of chemical space 
was represented (Figure 2.4).  Importantly, most compounds could be synthesized in 
significant quantities, permitting for follow-up in vitro and in vivo studies to be 
conducted without regard for compound scarcity. 
 Employing both hTERT-HMECs and PE cells, a four-day treatment assay with 
the 560-small molecule library was conducted by Dr. Keith Gligorich using a 20 µM 
concentration of each small molecule; following the conclusion of treatment, cell 
viability was assessed by quantifying cellular ATP-content and comparing control- and 
small molecule-treated conditions.  Then, using these measurements, hTERT-HMEC 
viability was compared to PE cell viability and an assessment of each small molecule’s 
cancer-selective cytotoxicity was conducted (Figure 2.5).  Selecting an arbitrary cut-off, 
the fourteen molecules with the highest degree of cancer-selectivity, representing 2.5% of 





















Figure 2.4.  Examples of the chemical scaffolds found within the small molecule 
library.  The small molecule library developed by the University of Utah Department of 













































































Figure 2.5.  Results of a small molecule library screen conducted using 
untransformed mammary epithelial cells (hTERT-HMECs) and patient-derived 
malignant pleural effusion cells (PE1007070).  Results are plotted as a difference in 
cell viability between hTERT-HMEC and PE1007070 cells as a measure of small 
molecule’s cytotoxic cancer-selectivity.  An arbitrary threshold (hit limit) was chosen to 



















































HMEC and PE cells were tested against a 12-point concentration range of the small 
molecules, instead of a single concentration, and EC50 values were calculated to better 
assess small molecule activity (Figure 2.6).  Collectively, the follow-up studies revealed a 
variety of dose response profiles, both in potency and in the degree of cancer-specific 





Models of breast cancer that accurately represent the human disease are 
indispensable for biomedical research aimed at improving patient survival outcomes.  In 
vitro and in vivo models contribute directly to our understanding of breast cancer’s 
molecular characteristics, genomic plasticity, interactions with host systems, and 
responses to treatment.  Breast cancer cell lines are ubiquitously employed as in vitro 
models of the disease and are excellent tools for the study of cell autonomous signaling 
pathways in cancer.  However, not all aspects of the disease found in patients are 
reflected in their use; compared to the primary breast tumor, cell lines are homogeneous 
in nature, have increased proliferation rates, and fail to model changes that occur over the 
course of patient treatment.  Considering these shortcomings, we chose to implement a 
preclinical model that uses patient-derived breast cancer cells for our investigations into 
the nature of late-stage, drug-insensitive cancers.  The cells used were derived from the 
malignant pleural effusions of breast cancer patients undergoing clinical treatment at the 
Huntsman Cancer Hospital.  Characterization studies revealed that the malignant PE cells 























Figure 2.6.  Results of follow-up studies examining the efficacies of fourteen 
molecules identified from the small molecule screen.  Twelve-point dose response 
analyses were used to measure the effects of the small molecules on the cell viabilities of 
untransformed mammary epithelial cells (hTERT-HMEC) and patient-derived malignant 
pleural effusion cells (PE1007070); experiment was performed by Dr. Keith Gligorich.  
Cells were treated with small molecules from the screen for four days then viability was 
measured by assessing cellular ATP content.  Values plotted represent the mean and 



























more closely matched the proliferation rates of tumors in patients and they also varied in 
their responses to in vitro drug treatment, variations likely resulting from patients’ 
adaptive responses to clinical treatment.  Together, these features suggested that the 
patient-derived PE cells could provide clinically relevant insight into the disease where 
cell lines would fall short. 
With the overall goals of advancing our general understanding of chemoresistance 
and identifying vulnerabilities of drug resistant cells that can be targeted therapeutically, 
a small molecule screen, together with hTERT-HMECs and patient-derived PE cells, was 
implemented as a means to identify chemical modulators of tumor-specific pathways.  
Small molecules identified from the screen could then be used as tools to elucidate 
mechanistic pathways, define new modes of drug-induced tumor cell death, and explore 
new strategies for treatment design and development.  Using a library of compounds 
synthesized at the University of Utah Department of Chemistry, the two cell types were 
tested against the library and small molecules that resulted in cell death in tumor cells, 
but not in untransformed mammary epithelial cells, were used for follow-up studies.  In 
all, fourteen compounds were chosen for more detailed dose response analysis studies.  
These small molecules were found to induce cytotoxic effects in tumor cells at varied, 
low micromolar efficacies and produced diverse selectivity profiles, suggesting that the 
different chemical scaffolds modulated a variety of biological pathways.  This 
encouraging result hints at the existence of multiple, drug-targetable vulnerabilities and 
extends an optimistic outlook for future therapeutic drug design. 
In all, the incorporation of patient-derived malignant PE cells into the 
experimental design allowed for relevant, focused results to be obtained; while it would 
have been possible to identify small molecules with cytotoxic, cancer selective 
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phenotypes using breast cancer cell lines as a model, it is unlikely that all of the resultant 
molecules would be active in cells with altered drug sensitivities and naturally slower 
proliferation rates.  As such, this study highlights the benefits of using a breast cancer 




 Detailed descriptions of the materials and methods used for the study presented 
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THE SMALL MOLECULE C-6 PROMOTES CANCER-SELECTIVE 















Results of the studies presented herein have been previously published: Gligorich KM, 
Vaden RM, et al. (2013) Development of a screen to identify selective small molecules 
active against patient-derived metastatic and chemoresistant breast cancer cells. Breast 
Cancer Res 15(4):R58 and Vaden RM, Gligorich KM, Jana R, Sigman MS, & Welm BE 
(2014) The small molecule C-6 is selectively cytotoxic against breast cancer cells and its 
biological action is characterized by mitochondrial defects and endoplasmic reticulum 




Our limited understanding of the molecular processes of drug insensitive 
neoplastic cells has posed a significant challenge for the development of new treatment 
strategies.  Small molecules that elicit desired phenotypes can be used as molecular tools 
to probe and define biological systems.  We previously reported the identification of the 
small molecule C-6, which induces cytotoxic and cytostatic phenotypes in drug refractory 
tumor cells.  Using this small molecule as a chemical tool, studies were conducted to 
characterize the cellular pathways affected in an effort to identify dependencies and 
vulnerabilities of advanced stage cancers.  These studies revealed that C-6 induces cancer 
cell death via a caspase independent mechanism.  Additionally, the small molecule 
induces endoplasmic reticulum stress and alters mitochondrial morphology and function.  
Alterations in energetic homeostasis and metabolic profiles were also observed.  In all, 
these studies suggest that pharmacologic induction of mitochondrial and endoplasmic 




 The application of chemical tools to the study of biological systems has added 
significantly to our knowledge of molecular biology, cellular signaling, and disease 
states.  Well-known examples of molecules that have directly contributed to our 
understanding of cell systems include rapamycin, colchicine, and pioglitazone; these 
chemical tools have allowed scientists to elucidate mechanisms of cellular nutrient 
sensing, microtubule polymerization, and glucose metabolism and adipogenesis, 
respectively (1-4).  Previously, we reported the development of a chemical screen that 
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utilized malignant pleural effusion cells as a model of advanced stage cancer; these 
aggressive metastatic cells were derived from breast cancer patients whose disease had 
become resistant to treatment (5).  The screen was conducted with the purpose of 
identifying biologically active small molecules that could be used as tools to elucidate 
cellular mechanisms of advanced stage cancers and drug resistance; in all, fourteen 
molecules were identified for their cytotoxic, cancer-selective phenotypes.  Herein are 
described the results of mode of action studies conducted with C-6, one of the small 
molecules identified.  With the overall goal of uncovering vulnerabilities of 
chemoresistant tumor cells that can be targeted therapeutically, these experiments have 




The small molecule C-6 selectively affects cancer cells 
 Previously, we reported the identification of a novel diarylmethine-containing 
small molecule, C-6, for its biological activity against patient-derived malignant pleural 
effusion cells.  Additionally, while the molecule was found to reduce the viability of three 
different patient-derived tumor cell types, it did not significantly affect untransformed 
mammary epithelial cells (Figure 3.1A and 3.1B) (5).  Considering the paucity of patient-
derived malignant pleural effusion cells and the inherent limitations associated with their 
expansion in culture, we sought to identify additional models of breast cancer with which 
to conduct mechanistic studies; the additional models could also be used to assess the 
generality of C-6’s mode of action.  Turning to breast cancer cell lines, MCF-7, T47D, 





















Figure 3.1.  The small molecule C-6 is selectively cytotoxic against tumor cells.  (A) 
The small molecule C-6.  (B) Twelve-point dose response analyses of untransformed 
primary mammary epithelial cells (hTERT-HMECs) and three patient-derived malignant 
pleural effusion cells (PE1007070, PE1008032, and PE904557a) treated with C-6 for 
four days.  (C) 12-point dose response analyses of an untransformed primary mammary 
epithelial cell line (MCF-10A) and three breast cancer cell lines (MCF-7, T47D, and 











































point dose response analyses to assess the effect of the small molecule on cell viability.  
Opportunely, C-6 was found to affect each of the three cell types examined and the EC50 
values were comparable to the low micromolar efficacies observed with patient-derived 
cells (Figure 3.1C).  To further assess whether breast cancer cell lines might be used to 
complement patient-derived cells in mode of action studies, an untransformed mammary 
epithelial cell line (MCF-10A) was also tested against C-6.  As with the primary cells, C-
6’s activity was restricted largely to transformed cells and MCF-10A cells were only 
minimally affected, even at the highest concentrations tested.  Collectively, the low 
micromolar efficacy and selectivity for untransformed cell lines suggested that cell lines 
could be used reliably for mechanistic studies aimed at better understanding the basis for 
C-6’s biological activity.  
 
 
C-6 induces cell cycle arrest and caspase independent cell death 
in cancer cells 
 As a first approach towards elucidating mechanisms contributing to C-6’s ability 
to reduce tumor cell viability, experiments were conducted to probe the effect of the 
small molecule on cell cycle; alterations in cell cycle progression can be informative of a 
molecule’s mode of action if blocks occur in specific phases (e.g., mitosis).  Three breast 
cancer cell lines and one untransformed mammary epithelial cell line were treated with 
C-6 for either 24 or 48 hours.  Following the conclusion of treatment, the cells were 
incubated with a nucleoside analog (BrdU, bromodeoxyuridine), which is incorporated 
into newly synthesized DNA (6).  The incorporation, which is proportional to the degree 
of cellular proliferation, can be quantified by flow cytometry and further analyzed to 
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determine phases of the cell cycle present within the overall population.  The results of 
these experiments conducted by a colleague, Dr. Keith Gligorich, revealed that treatment 
with C-6 significantly reduced proliferation of breast cancer cells; untransformed 
mammary epithelial cells also experienced a reduction in proliferation but the change was 
not statistically significant (Figure 3.2).  Analysis of the cell cycle profile (i.e., S phase, 
G1/G0 phase, G2 phase, and mitosis) revealed that treatment with the small molecule 
resulted in an accumulation of cells in G1/G0 phase accompanied by a reduction of cells 
in S phase, again, an effect observed only in malignant cells.  In all, these initial studies 
further demonstrated the preferential nature of C-6’s effect on tumor cells and provided 
evidence to suggest that C-6 treatment inhibits progression from G1/G0 to S phase of the 
cell cycle in malignant cells. 
 Based on the results of the cell cycle analyses, follow-up experiments were 
designed to probe whether C-6 induced cytostatic phenotypes exclusively or if the small 
molecule also induced cell death since dose response analyses alone cannot differentiate 
between cytotoxic- and cytostatic-induced reductions in cell viability.  To assess 
cytotoxic characteristics, an AAF-Glo assay was employed; the assay can measure the 
total number of cells as well as the number of dead cells simultaneously and can therefore 
be used to assess cytotoxicity.  Examining both cell lines and patient-derived malignant 
pleural effusion cells, C-6 was found to elicit a cytotoxic phenotype in MCF-7, 
PE1007070, PE904557a, and PE1100025 cells and a cytostatic phenotype in MDA-MB-
231 and PE1008032 cells, suggesting that the observed reductions in cell viability could 
occur by either mechanism and were likely cell-type dependent (Figure 3.3).  
Interestingly, evidence has been presented to suggest that cytostatic effects can be as 





















Figure 3.2.  C-6-treatment alters cell cycle progression in tumor cells, but not 
untransformed cells.  A mammary epithelial cell line (MCF-10A) and three breast 
cancer cell lines (MCF-7, T47D, and MDA-MB-231) were treated with C-6 for either 24 
or 48 hours.  Relative proliferation was then assessed by measuring bromodeoxyuridine 
(BrdU) incorporation by flow cytometry.  Statistical significance (p-value ≤ 0.05) is 























































Figure 3.3.  C-6 promotes both cytotoxic and cytostatic phenotypes.  Four patient-
derived cell types and three cell lines were treated with C-6 for up to four-days in a time 
course study.  The relative numbers of live and dead cells were quantified using an AAF-
Glo assay.  Values plotted represent the relative number of dead cells and are the average 
of three replicates.  Error bars represent the standard deviation of the replicates measured.  

















































Furthermore, that C-6 induced cytostasis is followed by delayed cell death cannot be 
excluded as a mechanism of reduction in cell viability. 
 Upon observing that C-6 was capable of inducing cancer cell death, additional 
experiments were conducted as to determine whether cell death was accompanied by 
caspase activation.  Caspases participate in signaling cascades directly involved in 
apoptosis and their contribution to programmed cell death has been well characterized 
(reviewed in (8)).  Two methods were used to measure caspase activity: immunoblot and 
enzymatic Caspase-Glo assays.  Surprisingly, treatment of malignant pleural effusion 
cells and cell lines with C-6 revealed that the small molecule did not induce activation of 
caspases 3/7, 8, or 9 as compared to positive control-treated cells in either the 
immunoblot or the Caspase-Glo assays (Figure 3.4A and 3.4B).  These results suggest 
that the form of cell death induced by C-6 is not mediated by classic apoptotic signaling 
mechanisms. 
Considering other forms of cell death not mediated by caspases, we next sought to 
assess whether autophagy could be participating in the determination of cancer cell fate 
following treatment with the small molecule.  Autophagy describes a process of self-
degradation wherein cells can “recycle” intracellular components, which can help balance 
overall cellular energy levels (reviewed in (9)).  Intracellular components destined for 
degradation can be sequestered into double membrane-bound autophagosomes for 
decomposition by hydrolytic enzymes.  Microtubule-associated protein 1A/1B-light chain 
3-II (LC3-II), following its conversion from LC3-I via protein lipidation, is then recruited 
to the autophagosome membrane to facilitate additional autophagic processes (10).  As 
such, changes in LC3-II can be monitored via immunoblot experiments to assess cellular 





















Figure 3.4.  Treatment with C-6 does not stimulate caspase activity.  (A) Immunoblot 
analysis of PARP cleavage and caspases 3, 8, and 9 protein levels in cells treated with C-
6 for 48 hours.  Staurosporine and trail/doxorubicin were used as positive control 
treatment conditions; vinculin was used as a loading control.  Experiment was conducted 
in collaboration with Dr. Keith Gligorich.  (B) Measurement of enzymatic caspase 
activity in cells treated with C-6.  Staurosporine was used as a positive control.  Values 
plotted represent the average of three replicates; error bars represent the standard 
deviation of the replicates measured.  Statistical significance (p-value ≤ 0.05) is annotated 



























were treated with either C-6 or a positive control, chloroquine; in conjunction with a 
colleague, Dr. Keith Gligorich, immunoblot assays were then conducted to monitor 
changes induced in LC3-I and LC3-II protein levels.  With the exception of T47D breast 
cancer cells, no changes were observed in the eight cell types tested; T47D cells 
presented with an unexpected increase in both LC3-I and LC3-II (Figure 3.5).  This 
observation in T47D cells suggest that these cells respond to C-6 treatment by increasing 
the levels of LC3-I, either transcriptionally or by processing additional proLC3, and also 
that the autophagosome degradation may be inhibited, as evidenced by increased LC3-II.  
Collectively, the data suggest that C-6’s biological activity against cancer cells is 
generally not dependent upon the activation of autophagy, although context-dependent 
activation of autophagy cannot be excluded. 
 
 
Mitochondrial and endoplasmic reticulum stress are components 
of C-6’s phenotype 
 In an effort to further elucidate C-6’s mode of action in cancer cells, we next 
conducted a transcriptome profiling experiment to assess the effect of C-6 on gene 
transcription.  MCF-7 breast cancer cells were treated with either C-6 for three hours; 
following treatment, RNA was isolated and purified before analysis by next generation 
sequencing.  A differential expression analysis was then performed comparing C-6 
treatment to control treatment.  Interestingly, the results of the experiment revealed two 
key observations.  First, of the most differentially expressed genes whose expression was 
increased in C-6-treated cells, seven of the top twenty genes were associated with 























Figure 3.5.  Activation of the autophagosome marker LC3 is not compulsory for C-
6’s biological activity.  Protein was isolated from cells treated with C-6 for 48 hours and 
an immunoblot assay was used to detect changes in LC3.  The cytotoxic molecule 
staurosporine was used as a negative control and chloroquine was used as a positive 
control for the detection of LC3; α-tubulin was used as a loading control.  Experiment 




















































whose expression was decreased in C-6-treated cells, six of the top twenty genes were 
encoded by the mitochondrial genome (Figure 3.6A).  Furthermore, nearly every gene 
encoded by the mitochondrial genome was decreased in expression, suggesting that C-6 
induced broad perturbations in mitochondria. 
Based on the results obtained from the next generation sequencing experiment, an 
investigation into the impact of ER stress on C-6 treated cells was conducted.  In general, 
the ER stress response pathway can be activated during times of protein misfolding or 
accumulation following translation in the lumen of the ER.  Some of the cellular 
mechanisms used to abate ER stress include translation attenuation and increased 
expression of protein-folding chaperones (reviewed in (11)).  In order to assess ER stress 
levels, proteins known to participate in ER stress were assayed by immunoblot using cell 
lines that had been treated with C-6; these experiments were conducted by a colleague, 
Dr. Keith Gligorich (Figure 3.6B).  A marked increase in the expression of DDIT3 
(CCAAT-enhancer-binding protein homologous protein, CHOP), a transcription factor 
whose expression is increased during times of ER stress, was observed in MCF-7 and 
T47D cells but not in MCF-10A or MDA-MB-231 cells (12).  The expression of a 
protein-folding chaperone, GRP78, was increased in three breast cancer cell lines 
examined but not in a C-6 insensitive untransformed mammary epithelial cell line (13).  
Another protein involved in the ER stress response, EIF2α, was also assayed by 
immunoblotting; the phosphorylation of EIF2α is known to occur as part of a cellular 
response to ER stress (14).  Collectively, the relative levels of phosphorylated EIF2α 
following C-6 treatment were found to occur variably between the cell lines examined 
and the interpretation of the these results were confounded partially by the high basal 





















Figure 3.6.  Endoplasmic reticulum (ER) stress is induced following C-6 treatment.  
(A) A next generation sequencing experiment was conducted in triplicate with MCF-7 
cells treated with either 30 µM C-6 or DMSO as a vehicle control.  The values plotted 
represent the results of a differential expression analysis between the two treatment 
groups; the twenty most up- and down-regulated genes are shown.  (B) A panel of four 
proteins associated with the ER stress response was assayed by immunoblotting 





























in the phosphorylation status of c-Jun Kinase (JNK) were evaluated following treatment 
it has been previously reported that activation of the JNK pathway during ER stress can 
potentiate cellular prodeath mechanisms (15-18).  In all, every cell type tested presented 
with increased JNK phosphorylation following C-6-treatment although the kinetics of the 
expression varied over the course of the 48-hour treatment time course.  Considering the 
sum of experiments conducted, ER stress is likely a general component of C-6’s 
biological activity.  However, the variable response magnitudes suggest that the degree of 
ER stress may be cell type-dependent. 
 
 
C-6 treatment alters mitochondrial morphology 
During the course of our studies to characterize C-6’s mode of action, unique 
cytoplasmic vacuoles were frequently observed in cells treated with the small molecule.  
These features, however, were observed only in breast cancer cells and not in 
untransformed mammary epithelial cells.  Cancer cells developed cytoplasmic vacuoles 
shortly after exposure to C-6 and these vacuoles expanded in size and number as 
exposure time increased (Figure 3.7A).  In an effort to determine the origin and 
composition of these structures, transmission electron microscopy (TEM) imaging was 
conducted with MCF-7 breast cancer cells that had been treated with C-6; as a control, 
MCF-10A untransformed mammary epithelial cells were also included in the imaging 
experiment.  Surprisingly, the acquired images revealed that the cytoplasmic vacuoles 
induced by C-6 in cancer cells were distended mitochondria (Figure 3.7B).  Double-
membrane mitochondria with gross morphological defects were observed in C-6-treated 




















Figure 3.7.  C-6 treatment stimulates mitochondrial swelling and a subsequent 
vacuole phenotype in tumor cells but not untransformed cells.  (A) An untransformed 
mammary epithelial cell line and two breast cancer cell lines were treated with 30 µM C-
6; phase contrast images were acquired at 0, 12, and 24 hours to assess vacuole 
formation.  Scale bar represents 10 µm; arrows denote cytoplasmic vacuoles.  (B) 
Transmission electron microscopy images of C-6-treated cells reveal enlarged 
mitochondria in MCF-7 breast cancer cells, but not untransformed MCF-10A cells, 
treated with the small molecule.  Cells were exposed to 30 µM C-6 for 24 hours before 




























alterations in mitochondrial morphology between control and treated conditions.  
Paraptosis, a caspase independent form of programmed cell death, was considered as a 
possible explanation for these morphological observations because the cell death program 
is characterized by cytoplasmic vacuole formation, mitochondrial swelling, and ER 
dysfunction.  Furthermore, the paraptosis-associated vacuole phenotype can be prevented 
by pharmacologically inhibiting transcription and translation (19).  Therefore, 
experiments were conducted to assess whether the formation of C-6-induced vacuoles 
could be blocked by cotreatment with Actinomycin D or cycloheximide, inhibitors of 
transcription and translation, respectively.  Three breast cancer cell lines were treated 
with either C-6 alone or in combination with Actinomycin D or cycloheximide; 
subsequently, cells were stained with MitoTracker, a fluorescent mitochondrial marker, 
and live-imaged (Figure 3.8).  Consistent with others’ reports detailing features of 
paraptosis, C-6-induced mitochondrial swelling and cytoplasmic vacuolation were 
inhibited by both Actinomycin D and cycloheximide (20, 21).  In all, the results of these 
experiments reveal that C-6 treatment significantly alters mitochondrial morphology, 
which may implicate paraptotic processes as contributors to C-6’s biological activity. 
 
 
Energetic homeostasis is perturbed by C-6 treatment 
Upon discovering the marked affect of C-6-treatment on mitochondrial 
morphology, metabolomics profiling experiments were conducted to assess the impact of 
C-6 on the organelle’s function.  Specifically, metabolic intermediates related to the 
tricarboxylic acid (TCA) cycle, an ATP generating cycle that functions within 




















Figure 3.8.  Inhibitors of transcription and translation block the formation of C-6-
induced vacuoles.  Three breast cancer cells lines were treated with C-6 alone or in 
combination with Actinomycin D, a transcription inhibitor, or cycloheximide, a 
translation inhibitor.  After 24 hours of treatment, mitochondria were stained with 
































cancer cells and MCF-10A untransformed mammary epithelial cells as models; the cells 
were treated with C-6 for three hours, then TCA cycle intermediates quantified by gas 
chromatography-mass spectrometry analysis.  The results of these experiments revealed 
that MCF-10A cells exhibited decreases in NADPH, acetyl-CoA, and succinyl-CoA and 
increases in NADH; MCF-7 cells exhibited increases in AMP and decreases in succinyl-
CoA (Figure 3.9A).  These changes in TCA cycle intermediates suggest that cells 
experience energy imbalances as a result of C-6 treatment.  Furthermore, even while C-6-
insensitive MCF-10A cells do not develop swollen mitochondria as a result of treatment 
with the small molecule, these metabolomic data suggest that mitochondrial function is 
still altered. 
The altered metabolomics profile observed in C-6-treated cells prompted us to 
further examine mitochondrial function.  Using three breast cancer cell lines and one 
untransformed mammary epithelial cell line, experiments were conducted to measure 
cellular oxygen consumption since functional mitochondria consume oxygen in a manner 
that can be directly correlated to cellular energy production.  Cells were treated with C-6 
for 3, 6, 12, or 24 hours; then oxygen consumption was measured using a Seahorse 
Bioscience XF24 analyzer and exogenous small molecule mitochondrial stressors were 
added sequentially to the cells to assess the function of the electron transport chain.  
Interestingly, the experiments revealed that both C-6 sensitive and insensitive cells had 
decreases in oxygen consumption following treatment.  Furthermore, after 24 hours of 
treatment with C-6, oxygen consumption was completely abolished in all cell types tested 
(Figure 3.9B).  Further examining the fidelity of the electron transport chain as measured 
by cellular responses to the exogenously added mitochondrial stressors (i.e., oligomycin, 

















Figure 3.9.  Mitochondrial function is perturbed by treatment with C-6.  (A) A 
metabolomics analysis of an untransformed cell line (MCF-10A) and a breast cancer cell 
line (MCF-7) was conducted to measure levels of metabolites associated with the 
tricarboxylic acid cycle following treatment with 30 µM C-6 for three hours.  The 
experiment was conducted in triplicate and the reported values are the average of the 
replicates.  Metabolites whose levels were increased (i.e., p-value ≤ 0.05) are denoted in 
green; those whose levels were decreased are denoted in red.  (B) Cellular oxygen 
consumption was measured in cells treated with C-6 for either 3, 6, 12, or 24 hours.  
Mitochondrial stressors oligomycin (oligo), carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP), rotenone (rot), and myxothiazol (myx) were added 
sequentially during the measurement procedure to assess the function of the electron 
transport chain.  Values plotted represent to average of three replicates whose values 
were normalized to total protein; error bars represent the standard deviation.  (C)  C-6 
was added to MCF-7 cells while measuring oxygen consumption.  Values plotted 
represent the average of three replicates whose values were normalized to total protein; 
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I and III inhibitors, respectively), no apparent defects were observed (22).  In an effort to 
elucidate the kinetics of C-6’s effect, an experiment was conducted with MCF-7 cells 
wherein the small molecule was added to untreated cells simultaneously while measuring 
oxygen consumption.  Interestingly, C-6 was found to immediately reduce cellular 
respiration upon its addition to cells (Figure 3.9C).  Collectively, the results of these 
studies revealed that C-6 dramatically affects cellular oxygen consumption.  Also, these 
results indicate that the presence of mitochondrial swelling, as was observed in cancer 
cells by TEM imaging, is not a sole predictor of respiratory defect. 
 Mitochondrial defects and respiratory dysfunction have been reported to be 
associated with the production of reactive oxygen species (ROS) and general oxidative 
imbalance (23, 24).  Considering this, experiments to establish whether C-6 induced 
oxidative imbalances were employed.  Four cells types, including both malignant and 
nonmalignant types, were treated with C-6 in a time course experiment.  Utilizing the 
indicator 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), whose intracellular 
oxidation to the fluorescent 2',7'-dichlorofluorescein (DCF) can be measured by flow 
cytometry, the cells were stained following the completion of treatment and fluorescence 
measured (Figure 3.10A).  A significant increase in intracellular fluorescence was 
observed in three breast cancer cell lines following a time course treatment with C-6 
while no increases were observed in an untransformed mammary epithelial cell line.  
Considering the possibility that oxidative imbalances or ROS may be responsible for C-
6’s cytotoxic effect in cancer cells, experiments were designed wherein cells were treated 
in combination with C-6 and exogenously added antioxidants; the ability of the 
antioxidants to rescue cell death was then assessed by measuring cell viability using an 

















Figure 3.10.  C-6-treatment alters redox homeostasis preferentially in tumor cells.  
(A) A mammary epithelial cell line (MCF-10A) and three breast cancer cell lines (MCF-
7, T47D, and MDA-MB-231) were treated with C-6 for up to 48 hours.  The cells were 
then stained with 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) whose 
intracellular oxidation generates the fluorescent molecule 2',7'-dichlorofluorescein 
(DCF); quantification of fluorescence was accomplished by flow cytometry.  Values 
plotted represent the mean of three independent replicates whose values were normalized 
to a vehicle-treated control; error bars represent standard deviation.  Statistical 
significance is annotated with one (p-value ≤ 0.05) or two (p-value ≤ 0.01) asterisk(s).  
(B) Twelve-point dose response analyses were conducted with MCF-7 cells; cells were 
treated with increasing concentrations of C-6 alone or in combination with N-
acetylcysteine (NAC), N-(2-mercaptopropionyl)-glycine (NMPG), butylated 
hydroxyanisole (BHA), or ascorbate.  Values plotted represent the average of three 































(2-mercaptopropionyl)-glycine (NMPG), butylated hydroxyanisole (BHA), and ascorbate 
were evaluated for their ability to reduce cell death.  Unfortunately, no antioxidant co-
treatment condition resulted in a rescue of C-6-induced cell death (Figure 3.10B).  
Collectively, these results suggest that C-6 induces oxidative imbalances but this 




 The chemical biology approach to the study of complex biological systems has 
and continues to be an effective method for understanding molecular processes and 
disease states.  Small molecules have been used to characterize protein-protein 
interactions, detail cellular signaling pathways, and define new therapeutic targets in 
disease (25).  Overall, the structural diversity that can be achieved with small molecules 
allows for their adaptation to many facets of life science.  One focus of the Sigman and 
Welm labs has been to identify vulnerabilities of cancer cells that can be targeted 
pharmacologically.  Utilizing a chemical biology approach, molecules that modulate 
signaling pathways specific to cancer cells have been identified.  The work presented 
here explores the biological activity of one of these molecules and aims to increase our 
understanding of cancer cell biology while providing insight into tumor cell 
vulnerabilities and dependencies. 
 Previously, our labs reported the development of a small molecule screen that 
utilizes patient-derived malignant pleural effusion cells; these cells were derived from 
breast cancer patients who had developed metastatic and treatment-refractory disease (5).  
The screen was designed to identify small molecules capable of eradicating tumor cells 
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preferentially over nonmalignant cells and the resulting molecules could then be used as 
molecular tools to mechanistically study the biological processes affected.  One such 
molecule, C-6, was chosen from the screen for its cytotoxicity against patient-derived 
malignant pleural effusion cells while being nearly inert against untransformed mammary 
epithelial cells.  Validation studies with other cell types revealed the generality of C-6’s 
effect: malignant cells were sensitive to treatment with the small molecule while 
untransformed cells were not.  Prompted by this finding, and even more so the finding 
that C-6 was active against chemoresistant cells, an investigation was initiated to 
understand the basis for C-6’s biological activity in tumor cells. 
Based on the design of the initial small molecule screen wherein C-6 was 
identified, it was expected that only molecules with cytotoxic phenotypes would be 
identified.  Molecules that induced cytostatic effects exclusively would not elicit a 
detectable response in the slowly proliferating malignant pleural effusion cells after only 
four days of treatment.  However, initial mode of action studies with a variety of cell 
types revealed that in tumor cells, the small molecule could promote both phenotypes, 
with each resulting in a decrease in cell viability overall.  Importantly though, 
untransformed cells were neither killed nor growth arrested following exposure to the 
small molecule. 
Further studies aimed to understand C-6’s mode of action in tumor cells revealed 
that the small molecule could induce caspase independent cell death.  Cellular programs 
of caspase independent cell death have been characterized and reported by others 
although the field has received less attention than classical caspase-mediated apoptosis.  
Autophagy, necroptosis, paraptosis, and necrosis are the most frequently reported forms 
of caspase independent cell death but other types not conforming to these modes have 
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been described (26-29).  Based upon the data presented here, necroptosis and necrosis 
cannot be excluded as possible mechanisms of C-6-induced tumor cells death.  More 
evidence (i.e., mitochondrial swelling and ER dysfunction) does support the idea that 
paraptotic programs are responsible for cell death promoted by exposure to the small 
molecule though.  Collectively though, caspase inactivity is a defining feature of C-6’s 
mode of action in cell types sensitive to the small molecule’s cytotoxic effects. 
Another defining characteristic of C-6’s biological activity is its profound effect 
on cellular energy homeostasis.  Tumor cells, but not untransformed cells, exposed to the 
small molecule develop prominent cytoplasmic vacuoles and the results of TEM imaging 
experiments clearly implicate enlarged mitochondria as the source of these features.  We 
were therefore surprised to find that both cell types, transformed and untransformed, 
experienced dramatic decreases in cellular oxygen consumption following treatment with 
C-6.  Taken together, these results indicate that mitochondrial swelling is not the source 
of respiratory disruption, but is likely a response to the disturbance.  Alternative energy 
production pathways (i.e., glycolysis outside of the mitochondria) are significantly less 
efficient in the production of ATP; oxidative phosphorylation within a mitochondrion can 
produce a maximum of 36 molecules of ATP while cytoplasmic glycolysis can produce a 
maximum of only 2 molecules of ATP (30).  Since even cells that are insensitive to the 
cytotoxic effects of C-6 experience decreases in oxygen consumption, it is expected then 
that their survival and continued proliferation is dependent upon aerobic and glycolytic 
pathways for the production of ATP.  The idea that transformed cells do not possess the 
glycolytic capacity to survive disruptions in oxidative phosphorylation, however, is in 
opposition to the observation that tumor cells utilize the glycolytic pathway as their main 
energy producing pathway, a phenomenon known as the Warburg effect (31, 32).  In 
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summary, it is unlikely that C-6’s affect on mitochondrial respiration is the sole predictor 
of sensitivity to the molecule’s cytotoxic effects, although energetic dyshomeostasis is 
still likely to contribute to cell death via the induction of general cell stress. 
Considering the sum of the results presented herein, the presence of mitochondrial 
swelling and disruptions in cellular redox homeostasis are the strongest indicators of a 
cell’s response to C-6-treatment.  That is, C-6’s ability to reduce cell viability in tumor 
cells but not untransformed cells can be predicted based on the occurrence of these two 
characteristics.  Considering the redox dyshomeostasis, the imbalance is likely more 
complex then simply the production of ROS.  The oxidation of nonfluorescent 
H2DCFDA to florescent DCF, which was used to measure changes in cellular redox 
states, can occur via a variety of intracellular (33).  For example, probe oxidation has 
been reported to occur in the presence of cytochrome C or H2O2 in conjunction with 
redox-active metal activation (34).  Others have reported that intracellular iron 
distribution significantly affects probe oxidation (35).  In all, probe oxidation can still be 
interpreted as an indicator of changes in cellular redox states, although the exact 
molecular basis for the imbalance cannot be inferred.  With C-6-treatment, the failure of 
antioxidants to significantly rescue C-6 induced cell death may be an indicator of a metal-
based mechanism by which the redox imbalance occurs. 
 In conclusion, the results of the studies presented herein identify disruptions in 
several key biological processes following exposure to C-6.  Specifically, disruptions in 
cell cycle progression, mitochondrial respiration, and cellular redox homeostasis were 
discovered.  Considering these findings in the context of the original goal to identify 
vulnerabilities in drug-refractory tumor cells, insight into the development of new 
treatment strategies can be gained.  Specifically, perturbations in cellular redox 
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homeostasis may prove to be a generalizable mechanism to target chemoresistant tumor 
cells.  Further work to delineate the specific mechanism by which C-6 induces redox 
imbalances will be a necessary next step towards determining this, but the results 
presented here establish the foundation for future work defining new therapeutic targets 
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student’s t-test (unpaired) was used to assess statistical significance and a p ≤ 0.05 was 
considered statistically significant.  The following p-values were used to annotate 
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EFFORTS TOWARDS THE IDENTIFICATION OF THE BIOLOGICAL 







The application of small molecules to biological systems can provide significant 
insight into the complex cellular signaling mechanisms of both normal cellular function 
and disease states.  Beyond the identification of phenotypes of interest, defining the 
biological target of a small molecule represents a challenging but immensely informative 
step in the scientific process.  We previously reported the identification of a small 
molecule, C-6, which was identified from a phenotype screen utilizing malignant pleural 
effusion cells derived directly from drug refractory breast cancer patients.  The small 
molecule was found to kill cancer cells selectively over untransformed cells types in a 
caspase independent manner.  With the overall goal of identifying vulnerabilities of drug 
resistant neoplastic cells, experiments were conducted to identify C-6’s biological target 
and delineate the small molecule’s mode of action.  Two independent strategies were 
implemented to identify C-6-interacting proteins: an affinity based strategy and a genetic 
mutagenesis screen.  A C-6 variant containing a photoaffinity moiety was generated and 
used for protein crosslinking studies.  While the results of these studies suggest that C-6 
binds the protein TMEM109, the implications of this binding interaction on cell death 
processes remains unclear.  The results of the genetic mutagenesis screen using randomly 
genetrapped near-haploid cells were also inconclusive.  Presented herein are the results of 
these studies and experimental design modifications that may be useful for future studies 








 Elucidating the biological targets of small molecules identified from phenotype 
screens is frequently referred to as the “bottleneck” of drug discovery (1-4).  The 
complexity of biological signaling pathways and the sheer number of proteins whose 
functions have not been fully characterize consistently confound efforts to understand 
how small molecules operate in the cellular milieu.  Even with these challenges, a wealth 
of knowledge can be gained by understanding the mechanistic basis for a small 
molecule’s activity.  Furthermore, using molecular tools to define novel signaling 
pathways has broad implications outside of disease research and can provide information 
about normal and developmental processes as well.  Several approaches have been 
developed for the identification of small molecule binding partners including functional 
genetic, bioinformatic, and affinity-based strategies (5-8). 
 Previously, we reported the identification of a small molecule, C-6, with unique 
anticancer activity (9, 10).  The small molecule was found to selectively kill patient-
derived malignant pleural effusion cells, leaving untransformed cells largely unaffected.  
Importantly, these malignant pleural effusion cells were obtained from breast cancer 
patients who had developed drug refractory disease.  The discovery that C-6 was active 
against these particularly aggressive cell types prompted further investigations into its 
mechanism of action with the overall goal of identifying vulnerabilities of chemoresistant 
cells.  Considering the valuable insight that could be gained by understanding the specific 
biological pathways modulated by C-6, we initiated a series of experiments to identify 
proteins that interact with the small molecule.  Herein are presented the results of these 
studies in addition to technical insights gained during the project’s development that may 




C-6 analogs with cytotoxic profiles comparable to the parent molecule 
can be generated 
 As a first step towards our goal of identifying proteins that interact with the 
anticancer molecule C-6, we undertook an investigation to characterize how the structural 
components of the small molecule influenced potency and cancer-selectivity in whole 
cell viability assays.  A series of analogs that contained structural modifications to both 
the A-ring and B-ring of C-6 and also to the diarylmethine position were designed 
(Figure 4.1A).  The synthetic route to access the analogs was developed by Dr. Ranjan 
Jana, a colleague in the Sigman lab, and utilized scaffold precursors that were 
inexpensive and could be easily modified to incorporate a variety of functional moieties 
(Figure 4.1B).  Exploration of the chemical space included modifications such as 
exchange of the carbamate group on the A-ring for sulfonamide variants, removal of B-
ring arylmethoxy groups, and incorporation of functionality at the diarylmethine position, 
among other changes (Table 4.1). 
 In all, twenty-six analogs of C-6 were prepared; with these molecules in hand, 
experiments were next conducted to assess the effects of the analogs on cell viability of 
untransformed and transformed cell types.  Specifically, we sought to evaluate the 
potencies and cancer-selectivity profiles of the analogs as compared to the parent 
molecule C-6.  As such, 12-point dose response analyses were conducted with each of the 
molecules and cell viability was subsequently measured using a [3-(4,5-dimethylthiazol-
2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium salt (MTS) assay; 
MCF-10A mammary epithelial cells and MCF-7 breast cancer cells were used to measure 
























Figure 4.1  The anticancer small molecule C-6 can be easily accessed.  (A) Chemical 










































































a variety of cell responses was observed (Table 4.1).  First, conversion of the carbamate 
group to an arylsulfonamide derivative abolished the cancer-selective phenotype of the 
parent molecule with every sulfonamide analog examined.  Considering that analog 26 
contains an aryl group pendant to the A-ring in a manner similar to the sulfonamide 
analogs and that its cancer-selective profile is also altered, the reduction in cancer-
selectivity in both cases can likely be attributed to the presence of pendant aryl 
substitution.  Direct alterations to the B-ring of C-6 generated a variety of profiles in the 
dose response assay.  The efficacies of analogs 19 and 20 were comparable to C-6 while 
analog 24 had reduced potency overall, possibly a reflection of the compound’s 
solubility; a decrease in cancer selectivity was observed with analog 18, suggesting that, 
in general, substitution on the A-ring is necessary for cancer-selectivity.  In all, these 
results provided the preliminary information necessary for implementing additional 
experiments aimed at designing functional probes for the identification of proteins that 
interact with C-6 in the cellular milieu. 
 
 
C-6 analogs activate stress pathways in a manner similar to the 
parent molecule 
 Upon establishing the efficacies of the C-6 analogs in whole cell dose response 
assays, focused studies were conducted to assess biological processes affected by small 
molecule treatment; specifically, experiments were conducted to evaluate the degree of 
similarity between C-6’s mode of action and those of the analogs.  Five defining 
characteristics of C-6’s biological activity were chosen and analogs were evaluated 
against these criteria.  Analogs were evaluated for their propensity to induce cytoplasmic 
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vacuoles, ability to induce gene expression of the endoplasmic reticulum stress protein 
CHOP, effect on caspase activity, effect on oxygen consumption, and impact on cellular 
redox homeostasis.  In all, three analogs whose dose response profiles most resembled C-
6’s were chosen for mechanistic assessment and T47D cells were used throughout for the 
experimental studies.  The results of these experiments collectively revealed that each 
analog’s mode of action consistently mirrored C-6’s mode of action (Figures 4.2 and 4.3).  
As such, analogs whose dose response profiles match that of the parent molecule likely 
modulate similar signaling pathways and induce comparable forms of cellular stress.  
These results suggest that with C-6, dose response analyses can be used to inform the 
design of molecular probes for the study of molecule-protein interactions. 
 
 
A photoaffinity-labeled C-6 variant can be used to identify molecular 
binding partners 
 Using the knowledge gained from our analog studies, a variant of C-6 was 
designed that contained both a trifluoromethyl phenyldiazirine photophore and an alkyne 
in scaffold positions that were expected to minimally impact C-6’s biological activity 
(Figure 4.4A).  It was envisioned that the light-activated photophore could generate a 
covalent bond with nearby proteins and Click chemistry could subsequently be used to 
append a modified biotin moiety; after streptavidin protein isolation and purification, the 
covalently bound proteins could be identified by mass spectrometry analysis.  To begin, a 
synthetic route was developed to generate the molecule and its synthesis accomplished 
(Figure 4.4B).  With the C-6 variant in hand, an assessment of it effects against 






















Figure 4.2.  Treatment with analogs of C-6 produce cytoplasmic vacuoles and 
mitochondrial swelling similar to C-6.  T47D breast cancer cells were treated for 24 
hours with C-6, analog 3, analog 20, or analog 5.  Mitochondria were subsequently 



































































Figure 4.3.  Analogs of C-6 modulate biological pathways in a manner similar to the 
parent molecule.  Each experiment was conducted with T47D breast cancer cells and 
utilized 30 µM of either C-6, analog 3, analog 20, or analog 5; experiments conducted 
with staurosporine utilized a 1 µm treatment concentration. (A) Real-time polymerase 
chain reaction (RT-PCR) measurements of CHOP gene expression following 24 hours of 
treatment with either C-6 or the analogs.  Error bars represent the standard deviation of 
four measurement replicates.  Expression was internally normalized to a control gene, 
GAPDH. (B) Measurements of caspases 3/7, 8, and 9 activities were obtained following 
72 hours of treatment with the small molecules using a Caspase-Glo assay.  Values 
plotted represent the mean of three independent replicates and error bars represent the 
standard deviation.  (C) Oxygen consumption measurements following a 24 hour 
treatment with the small molecules were obtained using a Seahorse XF24 analyzer.  
Values plotted represent the mean of three independent replicates and error bars represent 
the standard deviation.  Each condition was normalized internally to total protein.  (D)  
To assess changes in oxidative homeostasis, cells were treated for 48 hours, then stained 
with 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA).  The oxidation of 
H2DCFDA to 2',7'-dichlorofluorescein (DCF) was then measured by flow cytometry.  
Values plotted represent the mean of three independent replicates and error bars represent 








































Figure 4.4.  The C-6-photoaffinity derivative activates cellular response pathways in 
a manner similar to C-6.  (A) Chemical structure of C-6-photoaffinity, an analog that 
incorporates a diazarine photophore functional group.  (B) Synthetic route to access C-6-
photoaffinity.  (C) Dose response analysis C-6-photoaffinity against MCF-10A mammary 
epithelial cells and MCF-7 breast cancer cells measuring changes in cell viability.  (D) 
Immunoblot analysis of CHOP expression in MCF-10A and MCF-7 cells treated for 24 






























viability was measured following the completion of a dose response assay and the results 
revealed a potency and cancer-selectivity profile comparable to that of C-6 (Figure 4.4C).  
Further evaluation of the photoaffinity probe’s mode of action was conducted to assess 
whether the analog stimulated expression of the endoplasmic stress protein CHOP in 
MCF-7 breast cancer cells; as with the parent molecule, the photoaffinity variant was 
found to induce expression of CHOP as measured via immunoblot experiments (Figure 
4.4D).  These results together suggest that photophore and alkyne incorporation do not 
significantly alter the mode of action of C-6.  Furthermore, these data suggest that 
photoaffinity labeling experiments with the C-6 cognate may be used to provide 
analogous information about C-6’s intracellular binding partners. 
 Before proceeding forward with cell-based studies, optimizations of the 
conditions necessary for successful photoactivation of the probe were conducted.  For 
these experiments, a synthetic precursor of the photophore used in the design of the C-6 
analog was employed.  The photophore precursor was diluted in methanol and 
subsequently irradiated with varying wavelengths of light.  13C NMR spectra of the 
resulting products were then analyzed for the incorporation of an alkyl-methoxy group 
originating from the methanol solvent used during irradiation.  Broad spectrum, as 
opposed to wavelength-selected light was found to be the most effective form of 
photoactivation and was chosen for implementation in the cell-based assays.  
 Following the completion of chemical and biological validation studies with the 
photoaffinity probe, systematic photoaffinity labeling experiments were initiated.  A 
general workflow was designed, beginning with cell lysate preparation and proceeding 
through trifluoromethyl phenyldiazirine photoactivation, biotinylation, bead purification, 
and protein resolution via polyacrylamide gel electrophoresis; electrospray ionization 
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Fourier transform ion cyclotron resonance (ESI-FTIC) mass spectrometry could then be 
used to identify proteins bound to the crosslinked photophore (Figure 4.5).  Implementing 
this workflow with MCF-7 breast cancer cells, anti-streptavidin immunoblotting was 
conducted against an aliquot of the biotinylated and bead purified lysate product to 
measure the efficacy of the labeling process; from these immunoblots, differential protein 
bands were detected between photoaffinity- and control-treated cell lysates (Figure 4.6).  
The optimized photoaffinity labeling experiment was conducted in duplicate and the 
resolved proteins from a single band (~21 kDa) were analyzed by ESI-FTIC mass 
spectrometry (Table 4.2).  One protein, TMEM109, was identified from both independent 
experiments, suggesting against a nonspecific binding interaction with the photoaffinity 
probe.  TMEM09 has been reported by others to be a transmembrane, ion-conducting 
channel capable of transporting both monovalent and divalent cations (11).  Based on our 
findings, further studies were implemented to probe the importance of TMEM109 in C-6-
mediated cancer cell death. 
 
 
A reduction in TMEM109 protein expression does not confer 
protection from C-6-induced cell death in breast cancer cells 
 Before embarking upon experiments aimed at understanding TMEM109’s role in 
C-6’s mechanism of action, we first sought to characterize the expression of TMEM109 
in a variety of cell types.  Breast cancer cell lines, patient-derived malignant pleural 
effusion cells, a leukemia cell line, and untransformed mammary epithelial cells were 
assayed by immunoblot for the expression of TMEM109 (Figure 4.7A).  All cell types 












































































Figure 4.6.  Photoaffinity crosslinking experiments result in differentially detected 
bands in control- versus C-6-photoaffinity-treated samples.  (A) Example 
immunoblot results following crosslinking and protein purification of MCF-7 cell lysates.  
Arrows denote differentially detected bands.  Anti-streptavidin antibody was used to 
detect crosslinked proteins.  (B) Results of a competition crosslinking experiment using 
C-6 and its photoaffinity analog.  Arrows denote differentially detected bands.  Anti-


































































Figure 4.7.  Assessment of TMEM109 expression.  (A) TMEM109 expression as 
measured by immunoblotting in eight cells types.  (B) Real-time polymerase chain 
reaction (RT-PCR) measurements of TMEM109 gene expression in MCF-7 cells 
transduced with one of four different shRNA-TMEM109-targeting lentiviruses.  (C) 
Measurement of TMEM109 expression following lysate preparation with either standard 






























breast cancer cells displaying the lowest levels.  Particularly interesting though was the 
observation that prominent, higher molecular weight bands reacting with the anti-
TMEM109 antibody between 50 and 75 kDa were detected only in MCF-10A cells, 
which are C-6 insensitive.  The results of these characterization studies suggested that 
TMEM109 was expressed ubiquitously in the cell types frequently employed in our 
studies of C-6 and also that the protein may function differently in C-6-insensitive cell 
types, perhaps providing an explanation for the small molecule’s cancer-selective 
phenotype. 
To understand the role of TMEM109 in C-6’s mode of action, shRNA-mediated 
knockdown of protein expression in MCF-7 cells was conducted using a lentiviral 
delivery system; it was hypothesized that a reduction in the expression of the C-6’s 
biological target would alter cellular sensitivity to the small molecule’s cytotoxic effects. 
One control construct and four constructs targeting expression of TMEM109, each with 
antibiotic selection markers, were employed for the experiment; following transduction, 
antibiotic selection was conducted to select for those cells expressing the expression 
construct.  Upon generation of the stably expressing lines, quantitative real-time 
polymerase chain reaction (RT-PCR) was performed to measure relative mRNA levels of 
TMEM109.  Based on the results of two primer sets used against TMEM109, each of the 
four shRNA constructs significantly reduced the mRNA expression of the gene compared 
to untransduced and control-transduced MCF-7 cells (Figure 4.7B).  Further analysis of 
protein expression knockdown efficiency by immunoblot revealed results consistent with 
the RT-PCR experiments and further indicated that the cells expressed lower levels of 
TMEM109 than the parental or control-transduced lines (Figure 4.7C).  Using two of the 
four TMEM109-shRNA lines in addition to control-transduced and untransduced MCF-7 
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cells, 12-point dose response assays were conducted with C-6 to measure changes in cell 
viability resulting from C-6 treatment (Table 4.3).  Unfortunately, no significant changes 
in the EC50 values between the four lines were observed.  These data suggest that 




Genetrap knockout of TMEM109 does not alter the cytotoxicity profile 
of C-6 in KBM-7 chronic myelogenous leukemia cells 
 Even while our shRNA experiments targeting expression of TMEM109 
successfully reduced the levels of proteins, we also considered the possibility that 
residual protein, even at low levels, may be sufficient to produce the cytotoxic effects 
observed in cells treated with C-6.  Therefore, we sought to incorporate knockout cells 
into our studies as a way to exhaustively explore the role of TMEM109 in C-6-mediated 
cancer cell death.  The KBM-7 cells line was derived from a patient with chronic 
myelogenous leukemia and upon characterization, was found to be haploid with the 
exception of chromosome 8.  As such, these cells are ideal for gene knockout and 
ablation studies since genes not residing on chromosome 8 exist as a single copy 
compared to a diploid system wherein at least two copies are present.  Therefore, our labs 
acquired commercially available KBM-7 and genetrap-TMEM109 KBM-7 cells with 
which to test the effects of C-6.  After conducting preliminary experiments to ensure that 
C-6 was effective against the parental KBM-7 line, a validation of the genetrap-
TMEM109 KBM-7 cells was conducted by assessing TMEM109 protein levels by 




















































Figure 4.8.  Genetrap-TMEM09 KBM-7 cells are not protected from C-6’s cytotoxic 
effects compared to control KBM-7 cells.  (A) KBM-7 and genetrap-TMEM109 KBM-
7 cells were assessed for TMEM109 expression by immunoblotting.  (B) Dose response 
analysis of C-6 against KBM-7 and genetrap-TMEM109 KBM-7 cells measuring 
changes in cell viability.  Values represent the mean of three measurements and error bars 
represent the standard deviation.  (C) Effects of 48 hour C-6-treatment as measured by 
propidium iodide staining and flow cytometry measurement.  Values represent the mean 
















































response assay was conducted with C-6 to measure the effects of C-6 treatment on cell 
viability (Figure 4.8B).  Additionally, cell viability was also measured by propidium 
iodide staining and flow cytometry in order to assess potential growth arrest phenotypes 
(Figure 4.8C).  Unfortunately, as with the shRNA experiments, no significant difference 
was noted between the parental line and the genetrap-TMEM109 line.  In all, these data 
fail to implicate TMEM109’s direct involvement in C-6’s mechanism of action; however, 
it is still possible that TMEM109 contributes to C-6’s biological activity but its 
contribution is complex and beyond the readout of the assays used herein. 
 
 
A haploid genetic screen was implemented to identify the biological 
target of C-6 
 Considering an alternative strategy to our affinity-based target identification 
approach, a genetic mutagenesis screen was designed using near-haploid KBM-7 cells to 
identify the target of C-6.  Utilizing an approach reported by Brummelkamp and 
coworkers, the near-haploid cells were infected independently with retroviral and 
lentiviral genetrap constructs (12).  Upon transduction, near-random viral integration of 
the genetrap construct into the genome produced clones with single or multiple gene 
disruptions.  Importantly, since near-haploid cells were utilized, most genetrap 
integrations produced dominant phenotypes, an effect that could not be achieved in 
diploid systems.  The genetrap-mutagenized cells were treated with C-6 for four weeks 
and surviving clones were analyzed for shared gene disruption features.  It was expected 
that disruption of genes important for C-6’s mechanism of action would produce a 
knockout effect and promote survival in the presence of C-6; the viral insertion sites of 
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surviving clones could then be analyzed and the null genes identified.  However, after 
analyzing the clones of cells surviving C-6 treatment, no consistent trends were observed 
in viral integration patterns, suggesting the cells survived long-term C-6 treatment by 





The data presented here details our efforts towards defining C-6’s protein binding 
partners using photoaffinity labeling and functional genetic strategies.  With the affinity-
based strategy, analogs of the small molecule were generated and tested against 
untransformed and transformed mammary epithelial cells to assess their effects on cell 
viability before synthesizing a photophore-containing variant of C-6.  This study was 
designed to better understand the relationship between C-6’s structure and its biological 
activity and the results ultimately provided the necessary insight for photophore 
incorporation.  After synthesizing the photoaffinity derivative, validation studies were 
conducted to ensure that the parent molecule and the analog modulated similar biological 
pathways.  The results of dose response studies and experiments designed to measure 
endoplasmic reticulum stress, a characteristic feature of C-6’s biological activity, 
suggested that the photoaffinity derivative elicited cellular phenotypes in a manner 
similar to C-6.  As such, labeling experiments were initiated and the resulting crosslinked 
proteins analyzed by mass spectrometry.  In two experimental replicates, a single protein, 
TMEM109, was detected in C-6-photoaffinity-treated samples but not control-treated 
samples.  As such, experiments were designed to better understand the role of TMEM109 
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in C-6-mediated cancer cell death. 
As a first step towards this goal, eight cell types including primary patient-derived 
malignant pleural effusion cells, breast cancer cell lines, and untransformed mammary 
epithelial cells were evaluated for endogenous TMEM109 protein expression by 
immunoblot; a band corresponding to ~23 kDa was detected in all samples with variation 
in relative levels observed between the different cell types.  Next, an shRNA-mediated 
knockdown of TMEM109 was performed in MCF-7 cells to determine whether reduced 
protein expression could alter cellular responses to C-6.  Unfortunately, TMEM109 
knockdown did not afford a survival advantage against C-6 treatment and no differences 
were observed between shRNA-TMEM109, control-transduced, and untransduced lines. 
C-6 was also evaluated against genetrap-TMEM109 KBM-7 cells, but as with the 
shRNA-TMEM109 experiment, no difference in viability was observed when compared 
to control cells. 
In all, our investigation into TMEM109’s involvement in C-6’s mechanism of 
action produced results that may support several hypotheses.  While nonspecific-binding 
interactions can lead to false discoveries in photoaffinity labeling studies, TMEM109 was 
identified from two independent experiments, which suggests a preferential binding 
interaction with the protein.  However, this interaction could be an off-target effect.  That 
is, small molecule-protein binding may occur but the protein is ultimately uninvolved in 
the small molecule’s mechanism of action.  Alternative to this hypothesis is that 
TMEM109 does contribute to C-6’s phenotype, but that other protein family members 
can carry out redundant functions and are also affected by the molecule.  With this 
hypothesis, shRNA-mediated knockdown and genetrap knockout experiments would 
prove ineffective.  Overall, the data suggest that C-6 does bind TMEM109, but the 
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experiments conducted do not distinguish between redundant protein effects and off-
target binding, which ultimately confounds the results obtained. 
Considering all aspects of our photoaffinity-based target identification strategy 
and the work as a whole, several modifications could be made to improve the success of 
future experiments implementing this strategy.  First, an inactivated photoaffinity analog 
could be immensely useful as a control for delineating nonspecific interactions of the 
photoaffinity probe itself.  Second, experimental reproduction will be helpful for 
identifying low-abundance proteins that may only appear as mass spectrometry hits in, 
for example, two out of every five experimental runs; considering this possibility, 
identifying trends over a larger data set could prove beneficial.  Third, significant 
advancements have been made in the field of proteomic mass spectrometry analysis.  
Application of more advanced analysis techniques could reveal trends that are otherwise 
hidden using standard analysis techniques.  Finally, the use of more sensitive 
instrumentation could allow for the identification of small molecule-protein complexes in 
total cell lysate.  Omitting gel electrophoresis and trypsin digest steps would significantly 
expand the number of proteins analyzed and would also negate the requirement for band 
visualization, a step that limits detection to highly abundant proteins. 
 The data presented herein describe our work towards identifying the biological 
target of C-6.  Considering C-6’s unique, cancer-selective phenotype, identifying its 
binding partners is necessary to fully elucidate its mechanism of action.  Although our 
results suggest that C-6 binds TMEM109, the experiments failed to identify its role in C-
6-induced cancer cell death processes.  Since TMEM109’s endogenous function has not 
been clearly defined, further investigations into its role in normal cellular function could 
provide information useful for tailoring future experiments aimed at defining its 
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Materials and methods for chemical synthesis 
General considerations.  Tetrahydrofuran (THF), dichloromethane (DCM), 
diethyl ether, and toluene were used from an alumina column solvent system (Innovative 
Technology, Inc.).  Triethylamine (TEA) was distilled over calcium hydride.  
Dimethylformamide (DMF) was stored over activated 3Å molecular sieves.  Unless 
otherwise noted all chemicals were purchased from Aldrich, Acros, TCI, EMD, or 
Mallinckrodt and used without further purification.  Also, all reactions were performed 
under a nitrogen atmosphere unless otherwise noted.  1H NMR spectra were obtained at 
300 MHz, 400 MHz or 500 MHz using Varian spectrometers.  1H chemical shifts are 
reported in ppm and referenced to CHCl3 at 7.26 ppm, CD2Cl2 at 5.32 ppm, or acetone-
D6 at 2.05 ppm.  13C NMR spectra were obtained at 75 MHz, 100 MHz or 125 MHz 
using Varian spectrometers.  13C chemical shifts are reported in ppm and referenced to 
CHCl3 at 77.16 ppm, CD2Cl2 at 53.84 ppm, or acetone-D6 at 29.84 ppm.  High resolution 
mass spectrometry (HRMS) data were obtained on a Waters LCP Premier XE instrument 
by ESI/TOF.  Infrared (IR) spectra were recorded using a Thermo Nicolet FT-IR.  All 
melting points (MP) are uncorrected and recorded on Thomas Hoover Unimelt capillary 
melting point apparatus.  The following abbreviations are used: EtOAc (ethyl acetate), 
TLC (thin layer chromatography). 
Preparation of C-6 and analogs 1-17.  The general route used to access C-6 and 
analogs 1-17 has been reported previously (10). 
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Preparation of analog 21.  A mixture of analog 18  (11 mg, 0.29 mmol, 1.0 
equiv.), phenyl azide (8.7 mg, 0.73 mmol, 2.5 equiv.), CuSO4 (0.3 mg, 0.02 mmol, 0.075 
equiv.), and freshly prepared 1M sodium ascorbate (0.004 mmol, 0.15 eq.) were 
combined in 2 mL of a 1:3 H2O:THF solution.  The reaction was stirred for 12 hours at 
room temperature.  THF was then removed by rotary evaporation, 5 mL of H2O was 
added, and the product extracted with EtOAc (3 x 5 mL).  The combined organic layers 
were dried over Na2SO4 and concentrated.  The product was purified by silica gel flash 
chromatography (30:70 EtOAc:hexanes) to afford analog 21.  Yield 76%. 
Preparation of analog 22.  For the synthesis of analog 22, 1-azido-2-(2-(2-
chloroethoxy)ethoxy)ethane was first prepared according to a previously published 
procedure (13).  A mixture of analog 18 (0.025 g, 0.073 mmol, 1.0 equiv.), 1-azido-2-(2-
(2-chloroethoxy)ethoxy)ethane (0.0857 g) and K2CO3 (0.03014 g, 0.22 mmol, 3.0 eq.) in 
1.5 mL of DMF was heated to 70 °C for 48 hours.  After cooling, the mixture was diluted 
with NH4Cl (10 mL) and extracted with EtOAc (2 x 10 mL), dried over Na2SO4, and 
concentrated. The product was purified by flash chromatography (30:70 EtOAc:hexanes) 
on silica gel to afford analog 22.  Yield 28%. 
Preparation of intermediate 4.1.  5-bromobenzene-1,3-diol was prepared 
following a previously published literature procedure (14).  NaH (60% in mineral oil, 
33mmol) was added to 50 mL of DMF and stirred under an N2 atmosphere.  The reaction 
was cooled to 0 °C and 5-bromobenzene-1,3-diol (3.1 g, 16.6 mmol, 1.0 equiv.) in 5 mL 
of DMF was added to the stirring mixture.  The reaction was stirred for 20 minutes.  To 
the mixture was added benzyl bromide (33 mmol, 2.0 equiv.).  The reaction was allowed 
to warm to room temperature and stirring continued for 3 hours.  The reaction was 
quenched with saturated ammonium chloride solution and diluted with diethyl ether.  The 
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organic layer was dried and concentrated and the crude product purified by silica gel 
flash column chromatography (5:95 EtOAc:hexanes).  Yield 91%. 
Preparation of intermediate 4.2.  Compound 4.2 was prepared following 
published literature procedure and purity assessed using 1H NMR (15). 
Preparation of intermediate 4.3.  An oven-dried round bottom flask fitted with a 
magnetic stirbar and a rubber septum was charged with compound 4.1 (3.9 mmol, 3.3 
equiv.).  The flask was purged with N2 and 10 mL of THF added via cannula.  After the 
solid was allowed to dissolve, the flask was cooled to -78 °C.  Dropwise while stirring, 
previously titrated n-BuLi (3.9 mmol, 3.3 equiv.) was slowly added.  The reaction was 
stirred for 1 hour at -78 °C before a solution of compound 4.2 (310 mg, 1.3 mmol, 1.0 
equiv.) in THF (10 mL) was added to the stirring mixture dropwise over 10 minutes.  The 
reaction continued to stir at -78 °C for 2 hours.  The reaction was then quenched with 
H2O and allowed to slowly warm to room temperature.  The product was extracted into 
EtOAc (2 x 10 mL), washed with brine (2 x 10 mL), dried over Na2SO4, and concentrated 
under reduced pressure.  The product, compound 4.3, was purified using silica gel flash 
column chromatography and 30:70 acetone:hexanes.  Yield 51%. 
Preparation of intermediate 4.4.  To a flask charged with compound 4.3 (353 mg, 
0.7 mmol) in 20 mL of dry DCM, 1 drop of concentrated HCl was added and the reaction 
stirred at room temperature until TLC indicated consumption of the starting material.  
The mixture was then dried over Na2SO4, and concentrated.  The final product was used 
immediately for the next step and was combined (210 mg, 0.4 mmol) with 10% Pd/C 
(0.08 mmol, 20 mol%) and 2.0 mL of MeOH.  The flask was fitted with a balloon of H2 
and the reaction stirred for 12 hours.  Then, the reaction mixture was passed through a 
plug of silica and concentrated to provide compound 4.4. 
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Preparation of intermediate 4.5.  Propargyl bromide (26 mg, 0.2 mmol, 1.0 
equiv.) was added to a stirring mixture of compound 4.4 (73 mg, 0.2 mmol, 1.0 equiv.), 
acetone (15 mL) and K2CO3 (183 mg, 1.3 mmol, 6.0 equiv.).  The reaction was heated to 
reflux and stirred for 16 hours.  Then, the mixture was allowed to cool to room 
temperature, filtered, and concentrated.  The product was purified by silica gel flash 
column chromatography (30:70 EtOAc:hexanes).  Yield 32%. 
Preparation of intermediate 4.6.  Before preparation of intermediate 4.6, 1,2-
bis(2-iodoethoxy)ethane was first prepared following a previously published procedure 
(16).  Then, compound 4.5 (13 mg, 0.03 mmol, 1.0 equiv.), 1,2-bis(2-iodoethoxy)ethane 
(130 mg, 0.3 mmol, 10.0 equiv.), and K2CO3 (49 mg, 0.3 mmol, 10.0 equiv.) were 
combined with acetone (5 mL) in a vial equipped with a magnetic stirbar.  The reaction 
was heated to reflux and stirred for 18 hours when TLC indicated complete consumption 
of starting material.  The mixture was filtered, concentrated, and purified using silica gel 
flash column chromatography (30:70 acetone:hexanes).  Yield 97%. 
Preparation of C-6-photoaffinity analog.  The trifluoromethyl phenyldiazirine 
photophore was prepared in good yield following a previous report (17).  Intermediate 
4.6 (12.1 mg, 0.02 mmol, 1.0 equiv.), the freshly prepared trifluoromethyl 
phenyldiazirine photophore phenol (40 mg, 0.2 mmol, 10.0 equiv.), and K2CO3 (54 mg, 
0.4 mmol, 20.0 equiv.) were combined with acetone (1 mL) in a vial equipped with a 
magnetic stirbar.  The reaction was heated to reflux and stirred for 18 hours.  The mixture 
was filtered, concentrated, and purified using silica gel flash column chromatography 
(30:70 acetone:hexanes).  Yield >99%. 
Preparation of analogs 23-26.  Analogs 23-26 have been synthesized previously 
and their general routes reported (18). 
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Characterization of previously unreported compounds 
Characterization of analog 7.  TLC (30:70 EtOAc:hexanes) Rf=0.20; 1H NMR 
(300 MHz, CDCl3): δ 1.30 (s, 9H), 1.54 (d, J = 7.14 Hz, 3H), 3.74 (s, 6H), 4.00 (q, J = 
7.28 Hz, 1H), 6.27-6.31 (m, 3H), 6.57 (s, 1H), 6.97 (J = 8.51, 2H), 7.09 (J = 8.51, 2H), 
7.43 (J = 8.79, 2H), 7.68 (J = 8.79, 2H); 13C NMR (75 MHz, CDCl3): δ 21.8, 31.1, 35.2, 
44.4, 55.3, 97.6, 106.0, 121.8, 126.1, 127.1, 128.5, 134.6, 136.4, 143.3, 148.7, 156.8, 
160.8; IR: 548, 569, 625, 642, 696, 733, 754, 834, 924, 1018, 1042, 1086, 1112, 1158, 
1203, 1223, 1291, 1339, 1397, 1427, 1459, 1510, 1594, 2837, 2963, 3256 cm-1; HRMS 
(M+Na)+: calcd. 476.1872, obsvd. 476.1870. 
Characterization of analog 8.  TLC (30:70 EtOAc:hexanes) Rf=0.24; 1H NMR 
(300 MHz, CDCl3): δ 1.55 (d, J = 7.14 Hz, 3H); 1.63 (s, 1H), 3.74 (s, 6H), 4.01 (q, J = 
7.26 Hz, 1H), 6.26-6.30 (m, 2H), 6.74 (s, 1H), 6.98 (d, J = 8.64 Hz, 2H), 7.13 (d, J = 8.37 
Hz, 2H), 7.89 (d, J = 9.06 Hz, 2H), 9.06 (d, J = 8.27 Hz, 2H);  13C NMR (75 MHz, 
CDCl3): δ 21.6, 44.4, 55.4, 97.5, 106.1, 122.8, 124.4, 128.7, 128.9, 133.4, 144.6, 144.7, 
148.4, 150.3, 160.9; IR: 552, 607, 667, 684, 737, 853, 926, 1018, 1090, 1155, 1204, 
1311, 1348, 1458, 1530, 1594, 2934, 2966, 3265 cm-1; HRMS (M+Na)+: calcd. 465.1096, 
obsvd. 465.1082. 
Characterization of analog 9.  TLC (30:70 EtOAc:hexanes) Rf=0.22; 1H NMR 
(300 MHz, CDCl3): δ 1.54 (d, J = 7.14 Hz, 3H), 2.38 (s, 3H), 3.74 (s, 6H), 3.99 (q, J = 
7.26 Hz, 1H), 6.29 (s, 3H), 6.58 (s, 1H), 6.95 (d, J = 8.65 Hz, 2H), 7.08 (d, J = 8.37 Hz, 
2H), 7.21 (d, J = 7.96 Hz, 2H), 7.63 (d, J = 8.37 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 
21.7, 21.8, 44.4, 54.4, 97.7, 106.1, 122.1, 127.4, 128.5, 128.5, 129.8, 134.5, 136.3, 143.4, 
143.9, 148.7, 160.8; IR: 544, 561, 667, 693, 811, 835, 912, 1042, 1068, 1090, 1155, 
1204, 1290, 1324, 1397, 1427, 1456, 1508, 1593, 3232 cm-1; HRMS (M+Na)+: calcd. 
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434.1402, obsvd. 434.1409. 
Characterization of analog 10.  TLC (30:70 EtOAc:hexanes) Rf=0.20; 1H NMR 
(300 MHz, CDCl3): δ 1.55 (d, J = 7.14 Hz, 3H), 1.60 (s, 1H), 3.82 (s, 1H), 3.74 (s, 6H), 
4.00 (q, J = 7.26 Hz, 1H), 6.28 (s, 2H), 6.58 (s, 1H), 6.94 (2, 1H), 6.97 (s, 1H), 7.07-7.12 
(m, 4H), 7.47 (q, J = 3.98 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 21.7, 44.4, 57.4, 97.6, 
106.1, 116.4 (d, JCF = 22.5), 122.4, 128.7, 130.0, 130.2, 134.1, 135.2, 143.9, 148.6, 160.9, 
163.6, 167; IR: 542, 559, 637, 668, 694, 709, 834, 924, 1018, 1041, 1089, 1149, 1203, 
1236, 1291, 1340, 1395, 1427, 1456, 1493, 1508, 1590, 2967, 3256 cm-1; HRMS 
(M+Na)+: calcd. 438.1151, obsvd. 438.1150. 
Characterization of analog 11.  TLC (30:70 EtOAc:hexanes) Rf=0.20; 1H NMR 
(300 MHz, CDCl3): δ 1.54 (d, J = 7.14 Hz, 3H), 3.74 (s, 6H), 3.82 (s, 3H), 3.99 (q, J = 
7.26 Hz, 1H), 6.29 (s, 3H), 6.59 (s, 1H), 6.88 (d, J = 9.06 Hz, 2H), 6.96 (d, J = 8.72 Hz, 
2H), 7.09 (d, J = 8.39 Hz, 2H), 7.68 (d, J = 9.06 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 
21.8, 44.4, 54.4, 55.7, 97.7, 106.1, 114.3, 122.1, 128.5, 129.5, 130.8, 134.6, 143.4, 148.7, 
160.8, 163.2; IR: 549, 565, 667, 835, 1092, 1143, 1260, 1336, 1393, 1427, 1456, 1497, 
1594, 2869, 2988, 3231 cm-1; HRMS (M+Na)+: calcd. 450.1351, obsvd. 450.1360. 
Characterization of analog 12.  TLC (30:70 EtOAc:hexanes) Rf=0.20; 1H NMR 
(300 MHz, CDCl3): δ 1.48 (d, J = 7.00 Hz, 3H), 2.86 (s, 6H), 3.71 (s, 6H), 3.92 (q, J = 
7.14 Hz, 1H), 6.23-6.27 (m, 3H), 6.76 (s, 1H), 6.82 (d, J = 8.65 Hz, 2H), 6.97 (d, J = 8.65 
Hz, 2H), 7.17 (d, J = 8.69 Hz, 1H), 7.42 (d, J = 8.41 Hz, 1H), 7.53 (d, J = 8.55 Hz, 1H), 
8.16 (d, J = 8.28 Hz, 1H), 8.47 (d, J = 8.64 Hz, 1H), 8.49 (d, J = 8.51 Hz, 1H); 13C NMR 
(75 MHz, CDCl3): δ 21.7, 44.4, 45.5, 55.3, 97.7, 105.9, 115.3, 118.6, 121.9, 123.2, 128.4, 
128.6, 129.7, 129.9, 130.4, 130.9, 134.4, 134.5, 143.3, 148.6, 152.1, 160.8; IR: 538, 572, 
622, 682, 696, 731, 788, 836911, 1018, 1043, 1143, 1202, 1231, 1316, 1392, 1427, 1454, 
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1509, 1592, 2788, 2834, 2937, 3272 cm-1; HRMS (M+Na)+: calcd. 513.1824, obsvd. 
513.1833. 
Characterization of analog 14.  TLC (30:70 EtOAc:hexanes) Rf=0.20; 1H NMR 
(300 MHz, CDCl3): δ 1.55 (d, J = 7.14 Hz, 3H), 3.74 (s, 6H), 4.01(q, J = 7.00 Hz, 1H), 
6.29 (s, 3H), 6.56 (s, 1H), 6.96 (d, J = 8.51 Hz, 2H), 7.11 (d, J = 8.37 Hz, 2H), 7.39 (d, J 
= 8.78 Hz, 2H), 7.66 (d, J = 7.66 Hz, 2H); 13C NMR (75 MHz CDCl3): δ 21.7, 44.4, 55.3, 
97.6, 106.1, 122.4, 128.7, 128.8, 129.4, 133.9, 137.6, 139.6, 144.0, 148.5, 160.8; IR: 553, 
616, 667, 696, 730, 754, 827, 910, 1014, 1041, 1092, 1158, 1203, 1288, 1340, 1396, 
1427, 1457, 1509, 1593, 2836, 2965, 3259 cm-1; HRMS (M)+: calcd. 454.0586, obsvd. 
454.0862. 
Characterization of analog 15.  TLC (30:70 EtOAc:hexanes) Rf=0.20; 1H NMR 
(300 MHz, CDCl3): δ 1.54 (d, J = 7.14 Hz, 3H), 3.70 (s, 6H), 3.96 (q, J = 7.26 Hz, 1H), 
6.27 (s, 3H), 6.90 (s, 1H), 6.97-7.07 (m, 4H), 7.54-7.65 (m, 2H), 7.73 (d, J = 1.92 Hz, 
1H), 7.76 (d, J = 1.79 Hz, 2H), 7.85-7.89 (m, 3H), 8.33 (s, 1H); 13C NMR (75 MHz 
CDCl3): δ 21.7, 44.3, 55.3, 97.8, 106.0, 122.2, 122.4, 127.6, 128.0, 128.6, 128.9, 129.0, 
129.4, 129.5, 132.1, 134.3, 135.0, 136.1, 143.6, 148.6, 160.8; IR: 547, 615, 644, 657, 
667, 696, 747, 816, 857, 923, 952, 1018, 1041, 1047, 1131, 1154, 1202, 1319, 1339, 
1393, 1428, 1457, 1509, 1593, 2968, 3261 cm-1; HRMS (M+Na)+: calcd. 470.1402, 
obsvd. 470.1407. 
Characterization of analog 16.  TLC (30:70 EtOAc:hexanes) Rf=0.22; 1H NMR 
(300 MHz, CDCl3): δ 1.54 (d, J = 7.14 Hz, 3H), 2.38 (s, 3H), 3.74 (s, 6H), 3.99 (q, J = 
7.26 Hz, 1H), 6.29 (s, 3H), 6.58 (s, 1H), 6.95 (d, J = 8.65 Hz, 2H), 7.08 (d, J = 8.37 Hz, 
2H), 7.21 (d, J = 7.96 Hz, 2H), 7.63 (d, J = 8.37 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 
21.7, 21.8, 44.4, 54.4, 97.7, 106.1, 122.1, 127.4, 128.5, 128.5, 129.8, 134.5, 136.3, 143.4, 
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143.9, 148.7, 160.8; IR: 544, 561, 667, 693, 811, 835, 912, 1042, 1068, 1090, 1155, 
1204, 1290, 1324, 1397, 1427, 1456, 1508, 1593, 3232 cm-1; HRMS (M+Na)+: calcd. 
434.1402, obsvd. 434.1409. 
Characterization of analog 17.  TLC (30:70 EtOAc:Hexanes) Rf=0.32; 1H NMR 
(300 MHz, CDCl3): δ 1.55 (d, J = 7.14 Hz, 3H), 3.74 (s, 6H), 4.00 (q, J = 7.26 Hz, 1H), 
6.28 (s, 3H), 6.61 (s, 1H), 6.96 (d, J = 8.52 Hz, 2H), 7.03 (d, J = 8.92 Hz, 2H), 7.10 (d, J 
= 8.37 Hz, 2H), 7.70, (d, J = 8.92 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 21.8, 44.4, 
55.4, 97.6, 106.1, 119.5, 122.4, 128.6, 129.3, 134.1, 135.3, 143.8, 145.1, 148.6, 160.8; 
IR: 555, 668, 714, 832, 924, 1018, 1042, 1090, 1127, 1158, 1203, 1222, 1285, 1341, 
1395, 1427, 1459, 1490, 1509, 1581, 2099, 2128, 2929, 2963, 3255 cm-1. 
Characterization of analog 21.  TLC (30:70 EtOAc:hexanes) Rf=0.39; 1H NMR 
(300 MHz, CDCl3): δ 1.50 (s, 9H), 1.58 (d, J = 7.14 Hz, 3H), 3.76 (s, 3H), 4.03 (g, J = 
7.26 Hz, 1H), 5.23 (s, 2H), 6.39-6.45 (m, 4H), 7.14 (d, J = 8.31 Hz, 2H), 7.25 (d, J = 9.31 
Hz, 2H), 7.43-7.46 (m, 1H), 7.53 (t, J = 7.81 Hz, 2H), 7.72 (t, J = 7.81 Hz, 2H), 7.99 (s, 
1H); 13C NMR (75 MHz, CDCl3): δ 21.5, 28.5, 44.5, 55.4, 62.1, 98.6, 106.7, 106.8, 
118.8, 120.7, 121.0, 128.2, 128.9, 129.9, 136.5, 137.1, 140.8, 145.1, 149.3, 152.9, 159.4, 
160.9; IR: 667, 1049, 1159, 1233, 1456, 1464, 1472, 1506, 1521, 1539, 1558, 1595, 
1615, 1652, 1683, 1699, 1716, 1733, 2932, 2970, 3331 cm-1; HRMS (M)+ : calcd. 
523.2321, obsvd. 523.2319. 
Characterization of analog 22.  TLC (30:70 EtOAc:hexanes) Rf=0.15; 1H NMR 
(500 MHz, CDCl3) δ: 1.51 (s, 9H), 1.50 (d, J = 7.14, 3H), 3.60-3.64 (m, 2H), 3.68-3.77 
(m, 9H) 3.81-3.84 (m, 2H), 4.00 (q, J = 7.26, 1H), 4.04-4.07 (m, 2H), 6.30 (m, 1H), 6.36 
(m, 2H), 6.40 (s, 1H), 7.13 (d, J = 8.3 Hz, 2H), 7.25 (d, J = 7.78 Hz, 4H);  13C NMR (100 
MHz, CDCl3): δ 21.9, 28.5, 42.9, 44.9, 44.5, 55.4, 67.4, 69.9, 70.8, 70.9, 71.6, 98.4, 
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106.4, 106.6, 118.8, 128.1, 136.4, 140.9, 160.0, 160.7; IR: 555, 617, 668, 714, 832, 924, 
1042, 1090, 1127, 1158, 1203, 1285, 1341, 1459, 1490, 1509, 1588, 2099, 2128, 2930, 
2972, 3321 cm-1. 
Characterization of intermediate 4.1.  TLC (5:95 EtOAc:Hexanes) Rf=0.33; 
MP=58-60 °C; 1H NMR (300 MHz, CDCl3): δ 5.00 (s, 4H), 6.54 (t, J = 2.33 Hz, 1H), 
6.77 (d, J = 2.19 Hz, 2H), 7.32-7.41 (m, 10H); 13C NMR (75 MHz, CDCl3): δ 70.4, 
101.5, 111.2, 123.1, 127.7, 128.3, 128.8, 136.4, 160.5; IR: 630, 674, 695, 733, 816, 907, 
1026, 1051, 1080, 1151, 1212, 1278, 1328, 1377, 1436, 1497, 1573, 1594, 2870, 3031 
cm-1; HRMS (M)+: calcd. 369.0490, obsvd. 369.0492. 
Characterization of intermediate 4.3.  TLC (20:80 EtOAc:hexanes) Rf=0.11; 1H 
NMR (300 MHz, CDCl3): δ 1.49 (s, 9H), 1.83 (s, 3H), 2.43 (s, 1H), 4.93 (s, 4H), 6.47 (s, 
1H), 6.63-6.66 (m, 3H), 7.20-7.37 (m, 14H); 13C NMR (75 MHz, CDCl3): δ 28.5, 30.9, 
70.2, 76.1, 80.7, 100.4, 105.6, 118.3, 126.6, 127.8, 128.1, 128.7, 136.9, 137.3, 142.4, 
150.8, 152.9, 159.8; IR: 647, 667, 696, 732, 836, 907, 1027, 1050, 1105, 1151, 1233, 
1289, 1315, 1367, 1404, 1436, 1453, 1498, 1520, 1592, 1652, 1700, 2929, 2975, 3032, 
3331 cm-1; HRMS (M+Na)+: calcd. 548.2413, obsvd. 548.2411. 
Characterization of intermediate 4.4.  TLC (30:70 EtOAc:Hexanes) Rf=0.17; 
MP=112-114 °C; 1H NMR (300 MHz, Acetone-d6): δ 1.47 (s, 9H), 1.52 (d, J = 7.3 Hz, 
3H), 3.94 (q, J = 7.1, 1H), 6.15-6.16 (m, 1H), 6.21 (m, 2H), 7.15 (d, J = 8.6 Hz, 2H), 7.45 
(d, J = 8.6 Hz, 2H), 8.0 (s, 2H), 8.27 (bs, 1H); 13C NMR (75 MHz, Acetone-d6): δ 22.1, 
28.5, 44.8, 79.8, 101.2, 107.0, 119.1, 128.5, 138.5, 141.3, 150.2, 153.8, 159.3; IR: 651, 
667, 695, 773, 835, 921, 990, 1017, 1064, 1098, 1156, 1249, 1312, 1367, 1392, 1411, 




Characterization of intermediate 4.5.  TLC (30:70 EtOAc:hexanes) Rf=0.31; 1H 
NMR (400 MHz, CDCl3): δ 1.51 (s, 9H), 1.55 (d, J = 7.1 Hz, 3H), 2.49-2.50 (m, 1H), 
3.98 (q, J = 7.1 Hz, 1H), 4.60 (d, J = 2.3 Hz, 2H), 5.17 (bs, 1H), 6.27-6.31 (m, 2H), 6.42-
6.45 (m, 2H), 7.10-7.16 (m, 2H), 7.23-7.26 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 
21.7, 28.5, 44.2, 55.94, 75.7, 78.6, 80.72, 99.9, 107.2, 108.2, 119.0, 128.2, 136.4, 140.8, 
149.5, 156.7, 158.9, 173.2; IR: 648, 667, 695, 731, 774, 834, 906, 963, 1016, 1044, 1155, 
1236, 1314, 1367, 1392, 1410, 1455, 1521, 1595, 1695, 2928, 2972, 3289 cm-1; HRMS 
(M+Na)+: calcd. 390.1681, obsvd. 390.1679. 
Characterization of intermediate 4.6.  TLC (30:70 EtOAc:hexanes) Rf=0.30; 1H 
NMR (300 MHz, CDCl3): δ 1.50 (s, 9H), 1.56 (d, J = 7.1 Hz, 3H), 2.50 (t, J = 2.3 Hz, 
1H), 3.25 (t, J = 6.7 Hz, 2H), 3.65-3.85 (m, 8H), 3.97-4.08 (m, 3H), 4.61 (d, J = 2.3 Hz, 
2H), 6.36-6.44 (m, 4H), 7.12 (d, J = 8.6 Hz, 2H), 7.25 (d, J = 6.7 Hz, 2H); 13C NMR (75 
MHz, CDCl3): δ 3.1, 21.9, 28.5, 44.4, 56.0, 67.5, 70.0, 70.4, 71.0, 72.2, 75.7, 78.7, 80.6, 
99.4, 107.2, 107.7, 118.9, 128.2, 136.5, 140.8, 149.2, 153.0, 158.7, 160.0; IR: 553, 625, 
667, 701, 749, 781, 824, 979, 1035, 1149, 1204, 1362, 1456, 1506, 1538, 2921, 3375 cm-
1; HRMS (M)+: calcd. 632.1485, obsvd. 632.1487. 
Characterization of C-6-photoaffinity analog.  TLC (30:70 acetone:hexanes) 
Rf=0.30; 1H NMR (300 MHz, CDCl3): δ 1.50 (s, 9H), 1.56 (d, J = 7.1 Hz, 3H), 2.49 (t, J 
= 2.7 Hz, 1H), 3.73 (s, 4H), 3.80-3.87 (m, 4H), 3.96-4.12 (m, 5H), 4.60 (d, J = 2.3 Hz, 
2H), 6.36-6.43 (m, 4H), 6.71-6.78 (m, 2H), 6.91-6.93 (m, 1H), 7.10-7.13 (m, 2H), 7.23-
7.29 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 21.9, 28.5, 44.5, 56.0, 67.5, 67.8, 69.8, 
70.0, 71.0, 71.1, 75.6, 78.7, 80.5, 99.4, 107.2, 107.7, 113.3, 115.9, 118.8, 119.1, 128.2, 
130.2, 130.7, 136.5, 140.8, 149.2, 153.0, 158.7, 159.2, 160.0; IR: 553, 623, 674, 699, 
781, 831, 915, 993, 1069, 1149, 1203, 1361, 1442, 1471, 1506, 1539, 1558, 1590, 1635, 
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1760, 1733, 2950, 3341 cm-1; HRMS (M+Na)+: calcd. 706.2716, obsvd. 706.2716. 
 
 
Materials and methods for biological studies 
General considerations.  General methods for the biological studies presented 
herein have been reported previously (9, 10). 
Photoaffinity labeling studies.  To prepare the buffer for photoaffinity labeling, 
radioimmunoprecipitation assay (RIPA) buffer was made using 50 mM Tris HCl, 150 
mM NaCl, 0.1 % sodium dodecyl sulfate (SDS), 0.5 % sodium deoxycholate, 1% Triton 
X100; an aliquot containing protease and phosphatase inhibitor cocktails and DTT was 
freshly prepared prior to each experiment.  Release buffer was prepared as follows: 2% 
SDS, 30 mM Biotin, 100 mM NaCl, 6 M Urea, 2 M Thiourea, 1x Phosphate buffered 
saline (PBS).  CuSO4 solution was prepared as follows: 0.01 M CuSO4 pentahydrate and 
0.1 M sodium ascorbate in dH20.   
Streptavidin-conjugated Sepharose beads were obtained from GE Healthcare 
(Pittsburg, PA, USA).  Endogenously biotinylated proteins were removed prior to the 
photoaffinity experiment using 75 µL of bead slurry/2 mg protein.  For each condition to 
be examined, 150 µL bead slurry/1 mg protein was utilized.  Before use, the beads were 
washed 4 x 300 µL of 1x PBS, centrifuging the beads at 50g for 30 seconds between each 
wash.  After the final wash, the beads were kept on ice until use. 
To prepare cell lysates, the media was decanted from a 10-cm plate of 70-80% 
confluent MCF-7 cells and the cells washed with 1x PBS.  To the plate, 1 mL of cold 1x 
PBS was added and the cells scraped off the plate.  The cell lysates were stored on ice 
throughout the remaining procedure.  The suspension was aspirated and transferred to a 
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microcentrifuge tube and the cells pelleted for 3 minutes at 3000 RPM at 4 °C.  The 
liquid was aspirated from the pellet and 50 µL of cold RIPA buffer was added.  The tube 
was vortexed until the pellet loosened then the lysates were sonicated for 20 seconds to 
ensure complete disruption of the cell membrane.  The lysates were pelleted again for 3 
minutes at 3000 RPM at 4 °C.  The soluble fraction was used for the remaining 
procedure.  A BCA assay was used to determine the concentration of protein and 50 µL 
of 20 µg/µL MCF-7 lysate was used for each condition to be examined in the 
photoaffinity experiment. 
Photoactivation and click chemistry was conducted as follows: The appropriate 
amount of photoaffinity probe or DMSO was added to each tube/condition (generally 
between 100 and 500 µM).  The tube was vortexed to mix well and then incubated on ice 
for 5 minutes.  Using the EXFO light source, each tube was irradiated for 2 minutes at 4 
cm distance.  The corresponding amount of biotin-azide derivative (at 100 µM 
concentration in DMSO) was added to the appropriate tubes and the tube vortexed to 
mix.  The freshly prepared copper master mix was added to the tube such that the final 
ratio was 100:100:1:10 of alkyne:azide:CuSO4:sodium ascorbate.  The tube was again 
vortexed then incubated at 36 ºC.  After 10 minutes, the tubes were vortexed again.  After 
an additional 15 minutes incubating at 36 ºC, 0.5 M EDTA was added to quench the 
reaction such that there was 1:1 copper:EDTA.  The lysates were then filtered through a 
7k Zeba spin column according to the manufacturer’s protocol. 
Using washed streptavidin beads, the protein lysate was added to the beads and 
diluted with 1 x PBS such that there was ~1 mg protein/150 µL beads/400 µL total liquid 
volume.  The suspension was placed on ice and rocked slowly for 30 minutes.  The beads 
were then pelleted at 50 RCF for 30 seconds and the supernatant transferred to a new 
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tube.  The beads were then washed as follows, pelleting the beads between washes: 1 x 
PBS (100 µL), 1 x PBS (100 µL), RIPA buffer (50 µL), RIPA buffer (50 µL), Release 
buffer (50 µL).  To the supernatant and each wash was added 4x Laemmli load buffer (3 
volumes protein solution :1 volume 4x Laemmli buffer).  The samples were boiled at 95 
ºC for 5 minutes then stored at -20 ºC until resolution by gel electrophoresis. 
Gel electrophoresis and immunoblotting was carried out as follows:  Generally, 
experiments were conducted using 10%, 1.5 mm hand-cast polyacrylamide gels with 4% 
stacking.  For samples to be submitted for mass spectrometry analysis, precast BioRad 
gradient gels (4-15%, 1.0 mm) were used.  After electrophoresis, proteins were 
transferred to MilliPore low fluorescence membranes using a wet transfer system at 95V 
for 90 minutes on ice.  The membranes were washed with TBS and blocked with 
Odyssey blocking buffer for 1 hour at room temperature.  After blocking, the membranes 
were probed with Streptavidin IRDye 800CW (1:2000) in Odyssey blocking buffer for 1 
hour at room temperature.  The membranes were washed with TBST and imaged using 
the Li-Cor odyssey imaging system. 
 
 
Generation of shRNA TMEM109 knockdown cell lines by 
lentiviral transduction 
 shRNA constructs   TMEM109 expression and a control construct were 
obtained from GE Healthcare Dharmacon (Lafayette, Colorado, USA).  High titer 
lentivirus was produced as described previously; MCF-7 cells were transduced at an MOI 
of 10.  Antibiotic selection was conducted for 5 days post-transduction and selection was 
validated by GFP analysis and flow cytometry (19).  Immunoblot measurements of 
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 Two primer sets were used for RT-PCR analysis of TMEM109 expression.  Set 1: 
5’-TTTGGTGGCGCGTTTCAGCG-3’ and 5’-ATTCAGCAGCTGTGCGGCGA-3’; Set 
2: 5’-AGGCCGGCTAGTCTCCGAGC-3’ and 5’-GGCTGCCATGACTGGGTCTTTCT-
3’.  GAPDH was used as an internal control: 5’-AAATTCCATGGCACCGTC-3’and 5’- 




KBM-7 haploid cell studies 
 KBM-7 and genetrap-TMEM109 KBM-7 cells were obtained from Haplogen 
(Vienna, Austria).  Cells were cultured in suspension flasks in IMDM containing 10% 
FBS with penicillin and streptomycin antibiotics.  Retroviral genetrap constructs were 
generously provided by Thijn Brummelkamp at the Netherlands Cancer Institute and the 
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THE SMALL MOLECULE ZINAAMIDOLE INDUCES ZINC  
DYSHOMEOSTASIS AND IS SELECTIVELY 

















Results of the studies presented herein have been submitted for publication: Vaden RM, 
et al. (2014) The novel small molecule zinaamidole induces Zn2+ dyshomeostasis and 




 The small molecule zinaamidole (ZNA) was identified from a screen utilizing 
malignant pleural effusion cells derived from drug refractory breast cancer patients.  
Follow-up studies with the small molecule revealed that it was cytotoxic against a variety 
of breast cancer cell types but not against untransformed mammary epithelial cells.  
ZNA’s ability to decrease the viability of drug insensitive cancer cells coupled with its 
innocuous effects in untransformed cells prompted further evaluation of its molecular 
mode of action.  Next-generation RNA sequencing experiments revealed that ZNA 
induced the transcription of metal trafficking genes MT1F, MT1X, MT2A, SLC30A2, 
and SLC30A1.  Further exploring the functional effects of ZNA on metal trafficking, 
CuSO4 and ZnSO4 were each found to modulate ZNA’s biological activity, with ZnSO4 
potentiating ZNA’s cytotoxicity selectively in malignant cells.  ZNA and ZNA/ZnSO4-
treatment were found to induce caspase independent cell death in cancer cells 
concomitantly with increases in LC3 expression.  Mouse mammary tumor studies 
revealed that ZNA and ZNA/ZnSO4 attenuated tumor burden and significantly increased 
animal survival.  Studies aimed at identifying the biological target of ZNA suggested a 
possible role for transient receptor potential (TRP) channel proteins and experiments to 




 Treatment-refractory cancers represent the largest obstacle to improving patient 
survival and decreasing disease mortality.  While initial responses to clinical cancer 
treatments are initially robust, most cancers will relapse with altered drug sensitivity 
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profiles.  As such, our labs sought to define biological pathways in drug insensitive 
malignant cells that can be targeted therapeutically.  To accomplish this goal, a chemical 
biology approach was implemented and a small molecule library screen was conducted 
using malignant pleural effusion cells derived from treatment refractory breast cancer 
patients (1).  With this screen, novel small molecules with cytotoxic phenotypes could be 
identified and subsequently used as tools to explore the biological pathways perturbed.  
Considering that many chemotherapeutics employed in the clinic are indiscriminately 
cytotoxic and often adversely affect healthy, nonmalignant cells, immortalized human 
mammary epithelial cells were included in the screen so that small molecules with 
cancer-selective phenotypes could be identified.  Fourteen candidate molecules were 
identified from the screen for follow-up studies.  Herein are described the results of 





The novel small molecule zinaamidole is selectively cytotoxic against 
cancer cells and induces the transcription of metal trafficking genes 
 We previously reported the development of a unique small molecule screen aimed 
at identifying novel molecules with cytotoxic, cancer-selective phenotypes (1).  One of 
these small molecules, zinaamidole (ZNA), was chosen for further investigation to 
elucidate the underlying mechanisms of its biological activity (Figure 5.1A).  Ultimately, 
the knowledge gained would be used to inform new therapeutic development strategies 


















Figure 5.1.  The small molecule zinaamidole (ZNA) is selectively cytotoxic against 
malignant cells.  (A) Structure of ZNA.  (B) Twelve-point dose response analyses of 
ZNA against immortalized human mammary epithelial cells (hTERT-HMEC) and 
malignant pleural effusion cells (PE1005339) derived from a drug refractory breast 
cancer patient.  Values plotted represent the mean of three replicates and the standard 
deviation.  (C) Twelve-point dose response analyses of ZNA against an untransformed 
mammary epithelial cell line (MCF-10A) and three breast cancer cell lines (MCF-7, 
T47D, MDA-MB-231).  Values plotted represent the mean of three replicates and the 
standard deviation.  (D) Clonogenic cell survival assay.  Cells were seeded in 
quadruplicate, exposed to ZNA for 24 hours, then cultured without the small molecule for 
21 days.  Colonies were stained with crystal violet then quantified.  Values plotted 
represent the mean of four replicates and the standard deviation.  (E) Representative 
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experiments were designed to assess the generality of ZNA’s affect on a variety of cell 
types.  Twelve-point dose response assays were conducted using malignant pleural 
effusion cells derived from a second breast cancer patient and viability was measured 
following the completion of treatment.  As with the initial small molecule screen, the 
results of the dose response assay revealed that ZNA was cytotoxic against the malignant 
cells (PE1005339) but did not significantly affect the untransformed mammary epithelial 
cells (hTERT-HMEC) (Figure 5.1B).  Further evaluating ZNA’s effects in different cell 
types, three breast cancer cell lines and one mammary epithelial cell line were treated 
with the small molecule.  Consistent with the findings of the previous experiments 
utilizing primary cells, ZNA was found to have a cancer-selective phenotype (Figure 
5.1B).  Additionally, comparable EC50 values were observed in all of the malignant cell 
types tested, suggesting a common mechanism of action.  Upon evaluating the generality 
of ZNA’s biological activity in different cell types, we next sought to establish whether 
ZNA induced long-term effects on cell survival and proliferation after a short treatment 
with the small molecule.  A clonogenic cell survival assay was employed and cells were 
treated with ZNA for a sublethal exposure time of 24 hours.  The cells were then allowed 
to grow in drug-free media for 21 days and resulting colonies were stained with crystal 
violet and quantified.  Interestingly, even at the lowest concentration of ZNA tested, a 
decrease in the number of colonies was observed in the three breast cancer cell lines 
tested; the proliferative capacity of ZNA-insensitive MCF-10A cells, however, was 
relatively unaffected (Figures 5.1D and 5.1E). 
 Encouraged by ZNA’s activity against a variety of tumor cell types in both short- 
and long-term assays, experiments were conducted to understand ZNA’s molecular mode 
of action.  A next-generation RNA sequencing experiment was employed to assess how 
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ZNA affected the transcriptome in MCF-7 breast cancer cells.  MCF-7 cells were treated 
for 3 and 12 hours with 30 µM ZNA and the transcriptome was profiled against control-
treated MCF-7 cells.  Following differential expression analysis, a significant induction 
of metal trafficking genes was observed at both time points (Figure 5.2A).  MT1F, 
MT1X, and MT2A were the most upregulated genes following ZNA treatment; these 
genes encode for members of the metallothionein family, which are small, cysteine-rich 
proteins capable of binding metals (2).  Metallothioneins are thought to play a role in 
cellular redox homeostasis via their participation in metal sequestration and their function 
has been studied frequently in the context of metal detoxification (3, 4).  In addition to 
increased metallothionein gene expression, ZNA also stimulated an increase in SLC30A2 
and SLC30A1 transcripts.  SLC30A2 and SLC30A1, also known as ZNT2 and ZNT1, 
respectively, function as transmembrane transporters of zinc.  More specifically, 
members of the ZNT protein family have been shown to export Zn2+ from the cytoplasm 
into either the extracellular domain or into cellular compartments and vesicles (5, 6).  
Collectively, the results of the transcriptome profiling experiment implicate metal 
dyshomeostasis as a component of ZNA’s biological activity, with the changes in 
SLC30A2 and SLC30A1 further suggesting a specific role for zinc perturbations. 
 Considering the findings of the next-generation RNA sequencing experiment, we 
sought next to establish whether the changes in metal trafficking gene transcription were 
ubiquitous among different types of ZNA-treated cells.  Four cell lines were treated with 
30 µM ZNA or a vehicle control and the relative gene expressions of MT1F, MT1X, 
MT2A, SLC30A2, and SLC30A1 were measured by real-time polymerase chain reaction 
(RT-PCR).  Consistent with the results of the RNA-sequencing experiment, the ZNA- 





















Figure 5.2.  ZNA induces the expression of metal trafficking gene transcripts.  (A) 
The most differentially expressed transcripts in 30 µM ZNA-treated MCF-7 cells 
(compared to control-treated cells) as measured by next-generation RNA sequencing.  (B) 
RT-PCR measurements of gene transcription following exposure to ZNA in four cell 
types.  (C) Flow cytometry quantification of FluoZin-3 fluorescence in four cell types 
following a time course treatment with ZNA.  (D) Flow cytometry quantification of 
FluoZin-3 fluorescence in four cell types following a 3-hour treatment with ZNA in 



























cells presented with similar trends in temporal induction; gene expressions were 
generally decreased following 24 hours of ZNA-treatment compared to 3 hours, 
suggesting a dynamic cellular response to ZNA-induced insult. 
 Upon establishing that metal trafficking genes were significantly upregulated in 
response to ZNA treatment in a variety of cell types, an investigation to ascertain whether 
the transcriptional changes reflected significant changes in functional metal trafficking 
was undertaken.  FluoZin-3, a fluorescent Zn2+ indicator, was used to measure changes in 
intracellular Zn2+ following a time course treatment with ZNA (Figure 5.2C).  MCF-7 
breast cancer cells presented with a 13-fold increase in fluorescence following 48 hours 
of treatment; the three additional cell types tested, however, presented with only modest 
changes in fluorescence.  Considering that the increased metal trafficking gene 
transcription identified from the RT-PCR experiments might attenuate ZNA-induced 
changes in intracellular Zn2+, cells were treated with Actinomycin D (ACTD), an 
inhibitor of transcription, in conjunction with ZNA and FluoZin-3 fluorescence was 
measured (Figure 5.2D).  As hypothesized, the inhibition of transcription resulted in 
increased levels of FluoZin-3 fluorescence in ZNA/ACTD treated cells as opposed to 
cells treated with ZNA alone, suggesting that increased gene expression at least partially 
mitigates the changes in intracellular Zn2+.  In all, the results of these initial experiments 
aimed to understand the basis of ZNA’s anticancer activity implicate metal 







Zn2+ and Cu2+ potentiate ZNA’s cytotoxic effects 
 Hypothesizing that ZNA-treatment stimulated increases in intracellular metal 
concentrations, we next implemented experiments to evaluate the combinatorial effects of 
ZNA and biologically relevant transition metals added exogenously to cells.  Four cell 
types were supplemented with six different transition metals and treated with 30 µM 
ZNA.  The cells were treated for 48 hours then viability was measured using an ATP 
quantification assay.  Surprisingly, two of the six transition metals were found to 
dramatically alter cancer cell viability when treated in combination with ZNA (Figure 
5.3).  CuSO4 and ZnSO4 both strongly potentiated ZNA’s cytotoxicity in cancer cells as 
compared to ZNA treatment alone.  In contrast, a differential response was observed in 
ZNA-insensitive MCF-10A cells: ZNA/CuSO4 resulted in a complete reduction in cell 
viability while ZNA/ZnSO4 had a minimal effect.  To further evaluate the effects of 
CuSO4 and ZnSO4 on ZNA-treated cells, a propidium iodide uptake assay was employed 
to measure cell death following 24 hours of treatment (Figure 5.4).  The results of the 
assay were consistent with the results of the transition metal screen—the three breast 
cancer cell lines tested were sensitive to both ZNA/CuSO4 and ZNA/ZnSO4, but the 
untransformed mammary epithelial cell line was only sensitive to ZNA/CuSO4.  As such, 
we hypothesized that the underlying mechanism of ZNA’s cancer selectivity was founded 
in zinc dyshomeostasis. 
The ability of CuSO4 and ZnSO4 to potentiate ZNA’s cell death phenotype in 
cancer cells was explored further in dose response assays.  Twelve-point dose response 
assays were conducted for 72 hours with ZNA alone, ZNA at varying concentrations with 
30 µM CuSO4, or ZNA at varying concentrations with 30 µM ZnSO4.  Following the 





















Figure 5.3.  CuSO4 and ZnSO4 potentiate ZNA’s affect on cell viability.  Four cell 
types were treated with ZNA alone or in combination with an exogenously added 
transition metal.  The cells were cultured for 48 hours then cell viability was measured 
using an ATP quantification assay.  Values plotted represent the mean of three replicates 






















































Figure 5.4. Combinatorial ZNA/ZnSO4 treatment selectively affects the viability of 
cancer cells.  Four cell types were treated with ZNA alone or in combination with CuSO4 
or ZnSO4.  The cells were cultured for 24 hours then cell viability was measured using a 
propidium iodide uptake assay and flow cytometry analysis.  Values plotted represent the 



































 (Figure 5.5).  Several notable features were observed from the results of the dose 
response assay.  First, of the four cell types examined, the MCF-10A cells were the most 
sensitive to ZNA/CuSO4, with CuSO4 potentiating the small molecule’s effects at low, 
nanomolar ZNA concentrations.  MCF-10A cells also responded to ZNA/ZnSO4 
treatment, but the diminished viability is likely an indicator of growth arrest as opposed 
to cell death; the nature of dose response assays does not strictly indicate cell death.  
MCF-7 and MDA-MB-231 cells had similar dose response profiles in each of the three 
treatment conditions.  Interestingly, a bimodal dose curve was observed with 
ZNA/ZnSO4 wherein very high doses of ZNA were less effective at reducing cell 
viability than some lower doses; this bimodal effect was not observed in T47D cells.  In 
all, the addition of exogenous CuSO4 and ZnSO4 to ZNA-treated cells significantly alters 
the potency of the small molecule and the different responses elicited by the two metals 




ZNA behaves as an ionophore and promotes Zn2+ uptake 
 Considering the cancer-specific, cytotoxic effects induced by ZNA/ZnSO4-
treatment, we next sought to understand how the combination treatment affected 
intracellular Zn2+ levels.  Therefore, experiments were conducted with FluoZin-3 to 
quantify intracellular Zn2+ following 3 hours of treatment with either ZNA alone or in 
combination with ZnSO4 (Figure 5.6A).  The results revealed remarkably high levels of 
intracellular Zn2+ in the three breast cancer cell lines evaluated; no less than a 34-fold 
























Figure 5.5. Combinatorial ZNA/ZnSO4 treatment selectively reduces cancer cell 
viability.  Twelve-point dose response analyses of ZNA against an untransformed 
mammary epithelial cell line (MCF-10A) and three breast cancer cell lines (MCF-7, 
T47D, MDA-MB-231).  Values plotted represent the mean of three replicates and the 













































Figure 5.6. Combinatorial ZNA/ZnSO4 induces significant increase in intracellular 
zinc.  FluoZin-3 was used to quantify ZNA-induced changes in intracellular zinc by flow 
cytometry analysis following treatment in standard culture media (A) and in zinc-free 












































in fluorescence.  In contrast, the MCF-10A cells presented with only a 9-fold increase, a 
result that further suggests a role for Zn2+ in ZNA’s cancer-selective mode of action. 
Further probing the ionophore-like affect of ZNA on cells, an experiment was 
designed to test how ZNA affected cells in Zn2+-free media.  Cells were treated for 3 
hours in Hank’s balanced salt solution with either ZNA or ZNA/ZnSO4, then stained with 
FluoZin-3 to measure intracellular zinc levels (Figure 5.6B).  In MCF-10A cells, 
combinatorial treatment induced a 43-fold increase while MCF-7 cells presented with a 
78-fold increase in fluorescence under the same conditions.  With both cell types though, 
no increase was observed with ZNA-treatment alone.  These findings suggest that 
intracellular Zn2+ stores are unlikely to be responsible for providing the high levels of 
cytosolic Zn2+ observed following treatment with ZNA.  As such, ZNA-stimulated 
plasma membrane permeation to extracellular zinc, via protein mediated transport or 
otherwise, is likely the source of the initial ion imbalance. 
Experiments were next conducted to validate the results of the FluoZin-3 
experiments and to further assess the specificity of the probe for Zn2+.  Inductively 
coupled plasma-atomic emission spectroscopy (ICP-AES) was used to quantify Zn2+ 
levels in four cell types treated with either ZNA or ZNA/ZnSO4; the relative ion 
concentrations were normalized to total protein following ICP-AES analysis.  The 
concentration of Zn2+ in MCF-7, T47D, and MDA-MB-231 cells was found to be 1.35, 
0.52, and 0.82 nanogram of Zn2+ per microgram of protein, respectively, following 
treatment with ZNA/ZnSO4 (Table 5.1).  With ZNA-insensitive MCF-10A cells, 
however, Zn2+ levels fell below the detection limit of 1.00 mg/L and the ion was not 
measured despite protein levels comparable to the three breast cancer cell lines.  Overall, 






































magnitudes of the values obtained from the FluoZin-3 experiments, comparable trends 
are readily apparent and suggest that Zn2+ dyshomeostasis is a specific contributor to 
ZNA’s phenotype. 
 Considering the significant increases observed in ZNA/ZnSO4-treated cancer 
cells, we next initiated an experiment to investigate how the excess Zn2+ might be stored 
or contained in cells.  Four cell types were treated for 3 hours with ZNA or ZNA/ZnSO4, 
then fixed and stained with Zinquin, a fluorescent zinc indicator (Figure 5.7) (7).  
Interestingly, MCF-10A cells treated with ZNA/ZnSO4 presented with increased nuclear 
Zinquin staining, whereas MCF-7 cells presented with strong, punctate cytoplasmic 
Zinquin staining under the same treatment conditions.  In contrast, no changes in 
fluorescent intensity or cellular localization were observed in T47D and MDA-MB-231 
cells.  In all, the results of the staining experiment suggest that varied, cell-type 
dependent mechanisms of ion sequestration and efflux may be employed following ZNA-
stimulated Zn2+ influx. 
 
 
Caspase independent cell death is induced in cancer cells treated 
with ZNA 
With the overall goal of defining biological pathways in drug resistant tumor cells 
that can be targeted therapeutically, we continued our efforts to fully characterize the 
anticancer effects of ZNA.  Employing a 5-ethynyl-2’-deoxyuridine (EdU) incorporation 
assay, the effects of ZNA and ZNA/ZnSO4 on cellular proliferation were assessed in four 
cell types; the incorporation of the nucleoside analog EdU into genomic DNA was 
























Figure 5.7. Treatment with ZNA/ZnSO4 promotes intracellular Zn2+ sequestration.  
MCF-10A and MCF-7 cells were treated for 3 hours with either ZNA or ZNA/ZnSO4, 





























 (Figure 5.8A).  After 24 hours of ZNA treatment, a complete cell cycle block was 
observed in MCF-7 and T47D cells; MCF-10A and MDA-MB-231 cells presented with a 
58 and 66% reduction in EdU incorporation, respectively, compared to controls.  After 
only 6 hours of ZNA/ZnSO4 treatment though, all three breast cancer cell lines presented 
with a complete block in proliferation while ZNA-insensitive MCF-10A cells had only a 
27% reduction in EdU incorporation.  Together, these data demonstrate the sensitivity of 
malignant cell types to ZNA/ZnSO4 and further suggest that innate Zn2+ trafficking 
pathways may play a direct role in determining a cell’s sensitivity to the small molecule. 
In an effort to establish the form of cell death induced by ZNA in cancer cells, 
experiments were next initiated to determine whether caspases mediated the cell death 
process.  Caspases 3, 7, 8, and 9 are proteases that play direct roles in apoptotic signaling 
processes in addition to other cell death programs (8, 9).  A Caspase-Glo assay was 
employed to examine the effects of ZNA- and ZNA/ZnSO4-treatment on caspase 
activation in three different cell types; as a positive control, the small molecule 
staurosporine, a broad protein kinase inhibitor, was employed.  MCF-7 cells were 
excluded from the assay due to their lack of functional caspase 3 (10).  The results of the 
assay revealed that neither ZNA nor ZNA/ZnSO4 activated caspase activity in any of the 
cell types tested (Figure 5.8B).  As such, the mechanism of ZNA-induced cell death 
likely proceeds through nonapoptotic pathways. 
Upon finding that ZNA induced cell death independent of caspase activation, 
ZNA-treated cells were evaluated for the induction of necroptosis.  Necroptosis, a 
caspase independent form of programmed cell death, is mediated by receptor interaction 
protein kinase 1 (RIP1).  Inhibition of RIP1 with the small molecule Necrostatin-1 can 




















Figure 5.8. ZNA stimulates caspase independent cell death in cancer cells.  (A) The 
affect of ZNA and ZNA/ZnSO4 on proliferation was measured by 5-ethynyl-2'-
deoxyuridine (EdU) incorporation and flow cytometry analysis.  Values plotted represent 
the mean of three replicates and the standard error of the mean.  (B) A Caspase-Glo 
enzymatic assay was used to detect caspase activity following ZNA treatment.  
Staurosporine (STS) was used as a positive control.  Values plotted represent the mean of 


























were treated with ZNA or ZNA/ZnSO4 for 24 hours and cell death was measured by 
propidium iodide staining; the small molecule shikonin was used as a positive control 
(Figure 5.9A) (12).  The results of the assay revealed that Necrostatin-1 did not 
significantly inhibit ZNA- or ZNA/ZnSO4-induced cell death, suggesting that the small 
molecule does not induce necroptosis. 
Failing to find evidence in support of apoptosis and necroptosis, we next 
considered that autophagy might be stimulated by ZNA-treatment.  Autophagy is a 
complex cellular “recycling” process wherein unnecessary cellular components are 
degraded via lysosomal pathways (reviewed in (13)).  To measure autophagic induction 
by ZNA, the expression of the protein LC3 was monitored by immunoblotting.  LC3-I is 
converted to LC3-II via lipidation and recruited to autophagosome membranes prior to 
lysosomal-autophagosome fusion (14).  Four cell types were treated with either ZNA or 
ZNA/ZnSO4 and assayed by immunoblotting; the autophagic inhibitor chloroquine, 
which induces the accumulation of autophagosomes, was used as a positive control 
(Figure 5.9B) (15).  With ZNA treatment alone, LC3-induction was observed only in the 
small molecule-sensitive cancer cell lines: MCF-7, T47D, and MDA-MB-231 cells.  In 
contrast, no induction was observed in the ZNA-insensitive MCF-10A cells.  With 
combinatorial treatment, T47D cells presented with a significant increase in LC3 protein 
expression, a slight increase was noted in MDA-MB-231 cells, a reduction was observed 
in MCF-7 cells, and no induction was observed in MCF-10A cells.  Considering that 
autophagy can stimulate both prodeath and prosurvival pathways, an experiment was next 
designed to delineate how these observed autophagic processes affected cell outcomes 
following small molecule treatment.  Cells were treated with chloroquine, an inhibitor of 


















Figure 5.9. Treatment with ZNA stimulates LC3 expression selectively in cancer 
cells.  (A) The ability of ZNA to induce necroptosis was assessed by treating cells with 
ZNA in combination with the RIP1 inhibitor Necrostatin-1 (Nec-1).  Cell death was 
assessed 24 hours after treatment initiation by propidium iodide staining and flow 
cytometry analysis.  Shikonin was used as a positive control.  Values plotted represent the 
mean of three replicates and the standard error of the mean.  (B) Results of an 
immunoblot experiment assessing LC3 expression in four cell types following treatment 
with ZNA.  (C) The effects of autophagic inhibition by chloroquine on ZNA-treated cells 
(72-hour treatment) was assessed by propidium iodide staining and flow cytometry 

































staining.  If autophagy contributed to prosurvival phenotypes, the ZNA/chloroquine 
combination treatment would be expected to result in more cell death than with ZNA 
alone.  Alternatively, if autophagy activated prodeath pathways, the ZNA/chloroquine 
combination treatment would be expected to result in less cell death than with ZNA 
alone.  The results of the experiment revealed that in T47D breast cancer cells, 
ZNA/chloroquine treatment attenuated cell death.  Differences in the combinatorial 
treatment condition were observed in the other cell types, but these changes likely reflect 
the effect of chloroquine treatment alone (Figure 5.9C).  As such, these results suggest 
that autophagic processes contribute to a prodeath phenotype in T47D cells but the role of 
these processes in other cell types is not immediately clear.  Furthermore, the results 
indicate that the induction of autophagic programs by ZNA may be cell-type dependent. 
Several forms of caspase independent cell death have been described to occur 
concomitantly with redox imbalances and oxidative stress (16-18).  To assess whether 
oxidative imbalances accompanied ZNA-induced phenotypes, cells were treated with 
ZNA or ZNA/ZnSO4 for up to 48 hours and the oxidation of 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA, DCF) was used as an indicator of 
oxidative imbalance; DCF fluorescence was measured by flow cytometry and 
subsequently normalized to the appropriate vehicle-treated control (Figure 5.10A).  The 
results revealed that ZNA alone stimulated a slight increase in DCF fluorescence; in 
contrast, combinatorial treatment of ZNA and ZnSO4 resulted in a statistically significant 
decrease in H2DCFDA oxidation in three breast cancer cell lines compared to their 
respective controls.  The decreased levels of H2DCFDA oxidation observed with ZNA 
and ZnSO4 combinatorial treatment are consistent with literature reports detailing a 





















Figure 5.10. The effects of ZNA-treatment on cellular oxidative homeostasis. (A) 
Cells were treated with ZNA or ZNA/ZnSO4 then stained with 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA), which can be oxidized intracellularly 
to 2',7'-dichlorofluorescein (DCF).  DCF fluorescence was measured by flow cytometry.  
Values plotted represent the mean of three replicates and the standard error of the mean.  
(B) The effects of N-acetylcysteine on ZNA-induced DCF fluorescence was assessed by 
flow cytometry.  Values plotted represent the mean of three replicates and the standard 


















































homeostasis (19-21).  Attempts to inhibit this increase with the antioxidant N-
acetylcysteine (NAC) were successful only with T47D cells; however, a concomitant 
decrease in fluorescence was observed in T47D cells treated with NAC alone, 
confounding its interpretation (Figure 5.10B).  Considering that MCF-10A cells treated 
with ZNA present with increased DCF fluorescence in a manner comparable to breast 
cancer cells and that NAC did not affect DCF fluorescence in three of the cell types 
examined, it is unlikely that oxidative imbalances contribute significantly to ZNA’s 
cancer-selective phenotypes.  
 
 
ZNA effectively decreases tumor burden in vivo 
With our overall goal of identifying biological pathways in transformed cells that 
might be targeted for therapeutic intervention, studies implementing whole organism 
models were implemented to further characterize ZNA’s mode of action.  We specifically 
sought to understand whether the metal trafficking pathways perturbed by ZNA in in 
vitro models were similarly modulated in an in vivo system.  To examine this, nontumor 
bearing FVB/NJ mice were treated via intraperitoneal injection with ZNA (100 mg/kg) or 
a matched vehicle control for 3 and 24 hours.  Subsequently, metallothionein gene 
expression was assessed in renal and hepatic tissue by RT-PCR as a measure 
of perturbations to metal trafficking pathways.  The results revealed that MT1 and MT2 
expression was increased after 3 hours of treatment in both tissue types but decreased 
following 24 hours of treatment.  Interestingly, this trend mirrors the results of the in 
vitro experiments utilizing cell lines wherein MT gene expression was increased acutely 
following exposure to ZNA but decreased following longer exposure times (Figure  
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5.11A).  Collectively, these data suggest that ZNA is bioavailable and also that the 
pathways stimulated by the small molecule in vitro are intact and responsive in a whole 
organism model. 
 Considering the promising results of the preliminary in vivo experiments, a study 
was designed to assess how ZNA affected tumor growth in a mouse mammary tumor 
model.  PyMT mouse mammary tumors were transplanted into the uncleared mammary 
fat pads of three-week old female recipient FVB/NJ mice (22).  Following three weeks of 
tumor growth, ZNA treatment was initiated.  Mice were treated once a day for 21 days 
and four treatment conditions were evaluated: ZNA (100 mg/kg administered via 
intraperitoneal), ZnSO4 (25 mM administered continuously for the duration of treatment 
via drinking water), a combination of ZNA and ZnSO4, and a control group (PBS 
administered via intraperitoneal injection).  As an endpoint, a tumor diameter greater than 
2 cm was established for the study.  Following the completion of treatment, the results 
revealed that both ZNA alone and ZNA/ZnSO4 significantly improved animal survival 
compared to control- or ZnSO4-treated groups, respectively (Figure 5.11B).  Furthermore, 
no general toxicity, acute toxicological responses, or losses in body weight were observed 
in the mice treated with ZNA or with the combination of ZNA and ZnSO4.  These 
exciting results suggest that the pathways modulated by ZNA in vitro are relevant and 
functional in in vivo models.  The lack of general systemic toxicity suggests a relatively 
wide therapeutic treatment window—a desirable trait for new therapies when considering 
the significant toxicity of currently used chemotherapeutics. 
 From the in vivo ZNA treatment study, we initiated an experiment to determine 
whether the tumor tissue from the study displayed altered levels of metallothionein gene 

















Figure 5.11. ZNA attenuates tumor growth in an in vivo mouse mammary tumor 
model.  (A) The expression of metallothioneins 1 and 2 (MT1 and MT2) was assessed by 
RT-PCR from renal and hepatic tissue in nontumor bearing FVB/NJ mice.  Mice were 
treated for 3 or 24 hours with either ZNA (100 mg/kg, intraperitoneal injection) or a 
vehicle control.  Raw RT-PCR values were internally normalized to β-actin.  (B) FVB/NJ 
mice were transplanted with PyMT tumors, which were allowed to grow for 3 weeks.  
Then, the following treatments were conducted for 21 days: Control (intraperitoneal PBS 
injection once per day), ZNA (100 mg/kg, intraperitoneal injection once per day), ZnSO4 
(25 mM administered continuously via drinking water), or combinatorial treatment (100 
mg/kg ZNA, intraperitoneal injection once per day and 25 mM ZnSO4, administered 
continuously via drinking water).  Statistical significance: Control versus ZNA, ** 
(p=0.01); ZnSO4 versus combinatorial treatment, ** (p=0.007).  (C) From this in vivo 
tumor study, the expression of metallothioneins 1 and 2 (MT1 and MT2) was assessed by 




























ZNA/ZnSO4-, ZnSO4-, and control-treated mice were analyzed for MT1 and MT2 
expression by RT-PCR.  A reduction in MT1 and MT2 expression was observed in all  
treatment groups relative to the control, with the ZNA/ZnSO4-treated mouse presenting 
with nearly undetectable levels (Figure 5.11C).  Considering the length of treatment time 
(23 days) in the context of the previous RT-PCR experiments, the results are consistent 
with the expectation that longer treatment times result in a depression of metallothionein 
gene expression.  Further validation experiments are needed to fully understand these 
preliminary in vivo gene expression findings though. 
 
 
Exploring the contribution of ion transport proteins to ZNA’s 
mode of action 
 Considering ZNA’s unique cancer-selective phenotype and its ability to 
significantly reduce tumor burden in an in vivo model of breast cancer, experiments were 
initiated to identify the target of the small molecule and to further characterize the 
molecular mechanism of action.  Based on the sum of our mechanistic data implicating 
metal ion dyshomeostasis as a key component of ZNA’s mode of action, we hypothesized 
that ZNA modulated ion channel proteins, which in turn promoted the uptake of 
extracellular metal ions.  Reviewing the literature, we identified three different protein 
families that were capable of transporting metal ions and could be localized to the plasma 
membrane, as opposed to strict intracellular localization.  Herein are described our efforts 
to elucidate the contribution, if any, that these protein families might make to ZNA’s 
phenotype. 
The ability of zinc and copper to potentiate ZNA’s cell death phenotype prompted 
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first the hypothesis that ZNA directly affected an ion channel capable of transporting 
both ions.  A thorough literature investigation revealed that the protein divalent metal 
transporter 1 (DMT1) was capable of transporting both zinc and copper (23).  If DMT1 
played a role in ZNA’s mechanism of action, a reduction in its expression would be 
expected to alter the sensitivity of cells to the small molecule.  To implement such an 
experiment, five lentiviral shRNA constructs targeting DMT1 were used to knockdown 
DMT1 expression in MCF-7 cells.  The efficiency of the knockdown in each line was 
assessed by RT-PCR (Figure 5.12A).  Using 30 µM ZNA, a selection experiment was 
then conducted with the five stably expressing shRNA-DMT1 lines, one transduction 
control line, and untransduced MCF-7 cells.  Cells were treated with the small molecule 
for 14 days to select for resistant cells.  Unfortunately, no surviving cells were identified 
in any of the lines, with the exception of the shRNA-DMT1 construct #4 line.  This line, 
however, was senescent following treatment with ZNA and proliferation did not recover 
even after removal of the small molecule.  The same result was obtained upon 
experimental reproduction with fresh virus and newly transduced cells, suggesting that 
the senescent phenotype was a result of the construct’s expression.  While the line did 
survive treatment, its failure to proliferate even aftqer removing ZNA from the media did 
not allow for further follow-up experiments to be conducted.  As such, the role of DMT1 
in ZNA-stimulated phenotypes remains unclear. 
The increased expression of zinc efflux proteins ZNT1 and ZNT2 following ZNA 
treatment, which likely occurs as a means to mediate the acute increase in intracellular 
zinc, prompted us to next evaluate the importance of zinc-specific influx proteins in 





















Figure 5.12.  Relative gene expression of DMT1 in shRNA-DMT1 knockdown MCF-
7 cells.  Five lentiviral constructs were used to knockdown expression of DMT in MCF-7 
cells.  RT-PCR measurements were conducted to assess the efficiency of knockdown.  



























































modulation of ZIP proteins, a family of 14 zinc transport proteins that function to 
increase cytosolic levels of zinc, could produce the Zn2+ phenotypes observed in treated 
cells (reviewed in (24)).  To examine the validity of this hypothesis, we first conducted a 
data analysis experiment profiling relative ZIP gene expression levels to assess whether 
the genes were expressed and if so, to what extent.  Normalized data from the next-
generation RNA sequencing experiment was extracted from the vehicle-treated control 
sample analyses and rank ordered according to expression (Table 5.2).  A variety of 
expression levels were observed within the family, with ZIP6 and ZIP7 having the 
highest expression levels in MCF-7 cells while ZIP2 and ZIP12 expression fell below the 
detection limit.  In all, these results define a general profile for the expression of ZIP 
proteins in these cells. 
Next, an experiment was designed to test the importance of ZIP protein family 
members on ZNA’s mode of action.  Considering that structural redundancy within the 
ZIP family might confound the results of experiments aimed at understanding the 
contribution of an individual ZIP protein, an alternative strategy was developed.  Using a 
pooled shRNA knockdown approach, constructs targeting the expression of the 14 ZIP 
family members (with a minimum of two constructs per gene) were pooled and used for 
the transduction of MCF-7 cells.  With this strategy, random viral integrations with 
constructs targeting multiple ZIP proteins would be expected within a single cell.  As 
such, the experimental design would allow for the identification of ZIP proteins whose 
function would normally be replaced by a family member with redundant activity.  
Despite the advantages of the pooled shRNA approach though, the experiment failed to 
generate clones with resistance to ZNA.  This result may be indicative of two 





























redundancy within the protein family is more pervasive than first hypothesized.  As such, 
the role of ZIP proteins in ZNA’s biological mechanism of action remains enigmatic. 
 Considering a different ion transport family, we next conducted experiments to 
investigate the importance of transient receptor potential (TRP) channel proteins in 
ZNA’s molecular mode of action.  TRP channels serve a variety of biological functions 
and their roles in pain sensing, ion transduction, and sensory perception (e.g., pressure, 
vibration, heat, taste, etc.) have been well documented.  At least 28 TRP family members 
grouped into six subfamilies have been identified in mammalian cells and their leitmotif 
of cation permeability extends largely to Ca2+, Mg2+, and Na2+ (reviewed in (25, 26)).  
More recently though, evidence has been presented indicating that some TRP channels 
can be permeated by other biological trace metals (27-31).  Zinc ion transduction via TRP 
channels has specifically been reported for TRPM7, TRPA1, TRPC6, TRPV6, TRPM3, 
TRPM6, and TRPML1 but additional TRP channels with this function may yet be 
discovered (32-38).  Considering that Zn2+ and Cu2+ potentiate ZNA-induced cell death, 
we hypothesized that TRP channels could be facilitating the uptake of these extracellular 
metal ions via direct ZNA-stimulated TRP activation.  To test this hypothesis, a small 
molecule inhibitor of TRP channels, N-(p-amylcinnamoyl)anthranilic acid (ACA), was 
employed.  ACA is frequently used as a broad spectrum TRP inhibitor and has been 
shown to specifically block TRPC6, TRPM2, TRPM8 channels; however, ACA’s 
molecular activity is not fully defined and the molecule may also have stimulatory effects 
on TRPC3, TRPC5, TRPV1 and TRPV4 channels (39, 40).  With the limited commercial 
availability of broad spectrum TRP inhibitors, ACA was considered a reasonable first 
option for examining the role of TRP channels in ZNA-induced cancer cell death.  As 
such, MCF-7 cells were treated with ACA in combination with either ZNA or 
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ZNA/ZnSO4 for 3 hours and intracellular Zn2+ was quantified with FluoZin-3 by flow 
cytometry analysis (Figure 5.13).  Interestingly, the combination of ACA with 
ZNA/ZnSO4 produced the highest levels of FluoZin-3 fluorescence—more than 2 times 
higher than ZNA/ZnSO4 and more than 80 times higher than control-treated cells.  This 
dramatic increase in fluorescence with the ACA/ZNA/ZnSO4 combination treatment 
suggests that TRP channels could be contributing directly to ZNA’s phenotype in cancer 
cells.  However, the ambiguity associated with ACA’s molecular targets confounds 
efforts to fully understand the underlying mechanism for this effect.  As such, 
experiments aimed at delineating the roles of individual TRP channels and their 





 Herein was described the mechanism of action of the small molecule zinaamidole 
(ZNA).  From a screen employing malignant pleural effusion cells obtained from drug 
refractory breast cancer patients, ZNA was identified for its ability to selectively reduce 
the viability of these cancer cells while leaving untransformed mammary epithelial cells 
largely unaffected.  With the overall goal of utilizing ZNA as a molecular tool to probe 
and define pathways in drug insensitive tumors that could be targeted therapeutically, we 
implemented experiments to understand the small molecule’s mode of action.  Upon 
assessing ZNA’s effects in different malignant and nonmalignant mammary epithelial 
cell types, we established a general profile of its activity and further validated the cancer- 






















Figure 5.13.  The broad spectrum TRP channel inhibitor modulates ZNA/ZnSO4-
mediated Zn2+ influx.  MCF-7 cells were treated with the TRP channel inhibitor N-(p-
amylcinnamoyl)anthranilic acid (ACA) in combination with ZNA or ZNA/ZnSO4 for 3 
hours.  Intracellular Zn2+ was then quantified by FluoZin-3 staining and flow cytometry 


























































then employed to better understand ZNA’s affect on the transcriptome.  These 
experiments revealed a stark increase in metal trafficking transcripts and provided crucial 
insight into ZNA’s mechanism of action. 
Considering the impact of ZNA on metal trafficking gene transcription, a 
biological trace metal screen was conducted to assess how exogenously added transition 
metals might affect ZNA’s biological activity.  The results of the screen revealed that 
CuSO4 and ZnSO4 strongly potentiated ZNA’s biological activity.  Curiously though, 
ZNA/CuSO4 was found to induce rapid cell death in all cell types while ZNA/ZnSO4 was 
found to be cytotoxic only against malignant cells.  This observation prompted the 
hypothesis that ZNA’s cancer selective phenotype could be attributed to small molecule-
induced perturbations in Zn2+ trafficking.  Further experiments aimed at defining the 
form of cell death promoted by ZNA treatment revealed the small molecule induced 
caspase independent cell death, with autophagic processes activated in ZNA-sensitive 
cell types.  These autophagic processes were found to contribute to activation of pro-
death pathways only in T47D cells; though, the role of autophagic induction in MCF-7 
and MDA-MB-231 cells remains unclear.  Interestingly, the T47D cells also displayed an 
altered temporal induction of metal trafficking genes following treatment with ZNA.  
While MCF-10A, MCF-7, and MDA-MB-231 cells presented with acute increases at 3 
hours followed by a reduction in expression at 24 hours, the T47D cells presented with 
acute increases at 3 hours followed by even greater increases at 24 hours.  The molecular 
basis for the different response kinetics is not known, but the induction of autophagic, 
prodeath pathways in T47D cells may be connected to these transcriptional responses. 
The ability of ZNA/ZnSO4 to induce acute increases in cytosolic Zn2+ 
concentrations was demonstrated by FluoZin-3 staining as well as with atomic emission 
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spectroscopy analyses.  ZNA/ZnSO4’s effects on cytosolic Zn2+ concentrations in 
untransformed cells was significantly attenuated compared to the three malignant cell 
types evaluated, further suggesting that innate, cell-specific Zn2+ transport mechanisms 
play an important role in determining a cell’s sensitivity to ZNA.  The results of 
experiments utilizing Zinquin, a stain used with fixed cells to assess intracellular Zn2+ 
localization, revealed that MCF-7 cells treated with ZNA/ZnSO4 had strong, punctate 
staining within the cytoplasm.  This result suggests that MCF-7 cells mitigate the 
molecular insult of ZNA by sequestering the excess ion into discreet, intravescicular 
pools, potentially zincosomes (5, 41).  In contrast to the result obtained with MCF-7 cells, 
MCF-10A cells presented with an increase in diffuse, nuclear Zinquin staining and no 
differences were observed in T47D and MDA-MB-231 cells compared to control-treated 
cells.  Taken together, these results suggest that cellular responses to acute Zn2+ increases 
are varied and that injury mitigation, whether via efflux or sequestration, are likely cell-
type dependent.  Additional imaging experiments conducted with brighter, more 
photostable Zn2+ fluorescent indicators should be implemented for more precise cellular 
localization studies. 
With the overall aim of defining pathways that can be targeted in drug refractory 
cancers, mouse models were utilized to determine whether ZNA’s mode of action in vitro 
translated to whole organism systems.  First, we sought to assess the bioavailability of 
ZNA and tested the small molecule’s ability to induce metallothionein gene expression in 
tissue from nontumor bearing mice.  The RT-PCR results were found to be analogous to 
the in vitro RT-PCR experiments: metallothionein gene expression was increased in renal 
and hepatic tissue following 3 hours of treatment, and depressed after a 24 hour-
treatment.  These results suggest that the pathways perturbed by ZNA in vitro are both 
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functional and responsive in a whole organism.  With this information in hand, a study 
was conducted to assess the affect of ZNA on the survival of mammary tumor bearing 
mice.  Both ZNA and ZNA/ZnSO4 had profound effects on animal survival and 
significantly attenuated tumor burden compared to their respective controls. 
Efforts to understand the biological target of ZNA led us to evaluate DMT1, ZIP 
proteins, and TRP channels, as each of these proteins/protein families have been reported 
to transport Zn2+ across the plasma membrane.  Knockdown experiments aimed at 
studying the roles of DMT1 and ZIP proteins in ZNA’s phenotype failed to produce 
evidence in support of their involvement.  Experiments conducted with a broad spectrum 
TRP channel inhibitor, ACA, in combination with ZNA and ZNA/ZnSO4, however, 
revealed a strong Zn2+ response in cells following treatment.  ACA/ZNA/ZnSO4-
treatment was found to significantly increase FluoZin-3 fluorescence in MCF-7 cells 
compared to ZNA/ZnSO4-treatment, suggesting a role for TRP channels in ZNA’s mode 
of action.  Unfortunately, the specificity of ACA’s activity against different TRP 
channels has not been fully detailed, leaving open questions as to which TRP channels 
may be contributing to ZNA’s phenotype.  Furthermore, whether ZNA may agonize or 
antagonize the activity of these TRP channels has yet to be determined.  Future 
experiments designed to test the involvement of TRP channels in ZNA’s mode of action 
must also take into account the multimeric nature of the proteins.  Structural studies have 
revealed that the channels are comprised of four individual TRP protein subunits, 
affording quaternary architecture (42, 43).  Furthermore, homo- and heteromeric 
assemblies of the subunits have been reported, adding a subtle layer of complexity to the 
interpretation of experiments designed to analyze individual TRP channels (44-46). 
The small molecule ZNA shows extraordinary promise for future investigations 
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aimed at defining biological pathways in drug refractory cancer cells that can be targeted 
therapeutically.  The work presented herein describes a significant step in the process of 
understanding ZNA’s mechanism of action, but important questions remain.  While our 
in vitro and in vivo experiments consistently highlight the cancer-selectivity of ZNA, the 
precise molecular reason for this phenomenon is unknown.  Differential ion transporter 
gene expression and differential trace metal trafficking programs are both plausible 
explanations for the ZNA’s selectivity profile and genome-wide expression studies 
utilizing large data sets to analyze relative metal trafficking gene expressions would 
provide insight into this hypothesis.  These bioinformatic studies could also be utilized to 
predict ZNA sensitivity in different malignancies, thereby generating an enrollment 
biomarker for future clinical trials with therapies designed to induce Zn2+ 
dyshomeostasis. 
In conclusion, the small molecule ZNA has provided a tool for both the study of 
normal biological processes and malignant disease states.  Substantial progress has been 
made towards understanding its biological mode of action but much of its biology has yet 
to be explored.  In all, the application of a chemical biology approach towards 
understanding complex biological systems has proven fruitful and ZNA’s expected 





All cells were cultured under standard conditions as described previously (1).  
MCF-7, MCF-10A, and T47D cells were a generous gift from Andrea Bild at the 
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University of Utah; MDA-MB-231 cells were obtained directly from the American Type 
Culture Collection (ATCC).  All cell lines were authenticated by the ATCC in 
conjunction with Promega using short tandem repeat analysis. 
 
 
Reagents and antibodies 
The small molecule ZNA was synthesized as reported by Gibbons, J. B., Looper 
R. E., et al. (manuscript in preparation).  Propidium iodide was obtained from Cell 
Signaling (Danvers, MA, USA).  The Zn2+ indicator FluoZin-3 was obtained from Life 
Technologies (Carlsbad, CA, USA).  Actinomycin D and chloroquine were obtained from 
Sigma (St. Louis, MO, USA).  Antibodies against LC3A/B (Cell Signaling) and α-
Tubulin (Sigma) were used at a concentration of 1:1000.  IR800CW and IR680 secondary 




Dose response and clonogenic cell survival assays 
All dose response assays were conducted as described previously (1).  Cell 
viability was measured using an ATPlite assay (PerkinElmer, Waltham, MA, USA) 
following the manufacturer’s protocol.  Clonogenic cell survival assays were conducted 







RNA was isolated using an RNeasy RNA isolation and purification kit (Qiagen, 
Hilden, Germany) per the manufacturer’s protocol.  Libraries were prepared for 
sequencing using standard Illumina protocols and sequencing was accomplished using an 
Illumina HiSeq instrument (Illumina, San Diego, CA, USA).  Following completion of 
sequencing, genome alignment was conducted using NCBI build GRch37 and differential 
expression analysis was performed using the RNAseq application, which wraps the 
DESeq Bioconductor package (http://useq.sourceforge.net/cmdLnMenus.html#RNASeq); 
statistical significance was calculated as described by Anders and Huber (48).  




Real-Time PCR (RT-PCR) 
In preparation for RT-PCR, RNA was isolated using an RNeasy RNA isolation 
and purification kit (Qiagen).  For tissue derived from mouse in vivo experiments, fresh 
tissue was homogenized using a TissueLyser II for 3 minutes at 30 Hz before isolating 
RNA.  For experiments designed to measure gene expression, RT-PCR was conducted 
using a LightCycler 480 (Roche, Basel, Switzerland) and KAPA SYBR FAST qPCR 
Master Mix (Kapa Biosystems, Boston, MA, USA).  Primers used have been reported 
previsouly (49).  All data were normalized to internal reference genes and relative gene 





Measurement of intracellular Zn2+ by FluoZin-3 staining 
Following the completion of treatment, the low serum (2% FBS) drug-containing 
media was removed and replaced with Hank’s Balanced Salt Solution (HBSS, Life 
Technologies) containing 2.5 µM FluoZin-3.  The cells were incubated with the indicator 
for 30 minutes at room temperature in the dark.  After staining, the cells were trypsinized, 
resuspended in HBSS containing 2% FBS, and relative mean fluorescence was measured 
by flow cytometry (FACscan, BD Biosciences). 
 
 
Measurement of cell death by propidium iodide staining 
Following the completion of treatment, media and floating cells were collected 
and combined with trypsinized adherent cells.  The cells were washed with 2% 
FBS/HBSS, and resuspended in a propidium iodide solution (Cell Signaling) for analysis 
by flow cytometry.  The percentage of propidium iodide positive cells for each treatment 
condition were averaged and normalized to the vehicle-treated control. 
 
 
Inductively coupled plasma-atomic emission spectroscopy 
(ICP-AES) analysis 
 Following the completion of a 3-hour treatment, the media was discarded and the 
cells washed with 1xPBS.  To each 10-cm plate, 1 mL of nitric acid (TraceSELECT Ultra 
for trace analysis, Sigma) was added directly to the plate.  The nitric acid mixture was 
submitted for inductively coupled plasma-atomic emission spectroscopy (ICP-AES) 
analysis following methods established by the Environmental Protection Agency (51).  
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The experiment was performed in triplicate for each cell line and a fourth plate of cells 
was used to measure total protein (BCA assay, Thermo Fisher, Waltham, MA, USA).  
The ICP-AES data were then normalized to total protein for each cell line used. 
 
 
Measurement of caspase activity 
Caspase activity was measured using the Caspase Glo assay system (Promega, 
Madison, WI, USA) following the manufacturer’s protocol. 
 
 
Western blot analysis 




Measurement of cellular proliferation 
5-ethynyl-2´-deoxyuridine (EdU, Life Technologies) incorporation was used to 
measure cellular proliferation.  Experiments were conducted according to the 
manufacturer’s protocol and analyzed as previously described (1). 
 
 
In vivo ZNA studies 
Mouse studies were conducted with the approval of the University of Utah 
Institutional Animal Care and Use Committee.  FVB/NJ mice were obtained from The 
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Jackson Laboratory (Bar Harbor, ME, USA).  In preparation for the in vivo study, EF1α-
PyMT mouse mammary tumors were generated in donor mice and the tumors resected 
and prepared as single cells as described previously by Smith et al. (22).  These cells 
were suspended in Matrigel (BD Biosciences) and injected (50,000 cells per 10 µL 
injection) into the uncleared mammary fat pad of 3-week old female recipient FVB/NJ 
mice.  Twenty-one days following the transplant, the mice were randomized and drug 
treatment was initiated; mice were treated once a day for 21 days and a tumor diameter ≥ 
2 cm was established as an endpoint.  ZNA (100 mg/kg) or the matched vehicle control 
was administered to each mouse via a 200-µL intraperitoneal injection of ZNA diluted 
into DMSO, then diluted into phosphate buffered saline to a final DMSO concentration of 
5%.  ZnSO4 was administered continuously for the 21-day treatment period to the 




The student’s t-test (unpaired) was used to assess statistical significance and a p ≤ 
0.05 was considered statistically significant.  Statistical significance between Kaplan-
Meier survival curves was measured by the Mantel-Cox test using Prism 6.0 (GraphPad 
Software).  The following p-values were used to annotate statistical significance: p ≤ 0.05 
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Cancer is a living, dynamic entity.  It is characterized by its ruthless drive to 
survive, but its opportunistic nature, paradoxically, leads it to exploit host resources until 
neither survives.  The combined cancer mortality rates of men and women declined by 
only 12.1% between the years of 1950 and 2010 (1).  This statistic is a direct reflection of 
the deep, innate complexity of cancer and its heterogeneous and adaptable nature.  
Significant, continued efforts aimed at understanding the molecular characteristics of 
cancer will be required by the scientific community if the disease is to be eradicated in 
our lifetimes. 
Herein was presented work describing our efforts to define biological pathways in 
drug insensitive cancer cells that can be targeted for therapeutic intervention.  
Considering the significant lack of therapies available to patients who have developed 
drug-refractory and metastatic malignancies following initial treatments with frontline 
chemotherapeutics, we sought to both define the underlying biology of chemoresistance 
and also to establish pathways that might be exploited for therapeutic gain.  
Implementing a chemical biology approach, we established a unique small molecule 
screen utilizing malignant pleural effusion cells derived from drug-refractory breast 
cancer patients.  Considering the relatively indiscriminant toxicities of currently 
prescribed chemotherapeutics, immortalized human mammary epithelial cells were 
incorporated into the screen such that molecules with cancer-specific phenotypes could 
be identified.  From this screen, fourteen novel small molecules were identified for their 
ability to reduce the viability of the malignant pleural effusion cells while eliciting little 
to no effect on untransformed mammary epithelial cells.  Two of these molecules, C-6 
and zinaamidole (ZNA), were chosen for further mechanistic studies. 
While the results of our studies revealed that C-6 and ZNA exerted their cancer-
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selective cytotoxic effects via different biological mechanisms, a common theme was 
observed: the induction of caspase independent cell death. The role of caspase signaling 
in cell death has been studied extensively; defects in caspase signaling and apoptosis 
have also been well documented in some cancers (2, 3).  As such, targeting caspase 
independent cell death may prove to be a beneficial strategy for the development of new 
therapeutics for late-stage, drug insensitive cancers.  In addition to the common theme of 
caspase independent cell death, ion dyshomeostasis may comprise a shared mechanistic 
trait between C-6 and ZNA, although this is less clear in the case of C-6.  Although 
evidence directly supporting the role of ion imbalances in C-6-induced cell death was not 
found, the characteristics of the cell death induced by the small molecule are consistent 
with ion dyshomeostasis.  Specifically, the induction of endoplasmic reticulum stress, the 
strong mitochondrial disruption phenotype, and the observed caspase independent cell 
death have all been reported to occur in conjunction with perturbations in ion 
homeostasis (4-8).  Considering then that both molecules may induce their cancer-
selective effects via ion channel modulation, this brings to light the idea that targeting ion 
channels may be a useful strategy for cancer treatment.  Furthermore, the cancer-selective 
nature of both molecules suggests that ion channels may be differentially expressed in 
malignant cell types such that wide therapeutic treatment windows might be obtained 
with an appropriately discerning drug.  This approach is not without caveats though.  Ion 
channels are expressed ubiquitously in every cell type and play critical roles in the 
function of excitable cells such as cardiac cells and neurons.  Considering this, in vivo 
testing will be critical in the early stages of preclinical research to establish the effects of 
new therapeutics on cardiac/muscle function and also on the central nervous system. 
In all, our multifaceted approach towards cancer research, incorporating 
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chemistry, molecular biology, and clinical oncology resources, has resulted in the 
identification of two molecular tools by which to investigate and untangle the 
complexities of cancer.  More broadly though, this approach has allowed for new insight 
into the disease, hinting at the promise of both caspase independent cell death and ion 
dyshomeostasis for future therapeutic development.  Despite the seemingly 
insurmountable research challenge presented by cancer, continued work is required to 
both define its origins and understand its vulnerabilities.  Each small gain in our 
understanding of the molecular characteristics of cancer leads us closer to the 
development of new prevention and detection strategies in addition to more focused, 
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